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Triple negative breast cancer (TNBC) is a highly aggressive type of 
breast cancer that accounts for 15-20% of breast cancer cases. Targeted 
therapy remains to be established for TNBC that lacks estrogen 
receptors (ERs), progesterone receptors (PRs) and human epidermal 
growth factor receptor HER2, and therefore fails to respond to 
hormonal and anti-HER2 treatment. This limits the therapy to 
traditional chemotherapy, radiation and surgery, which is only 
beneficial to a fraction of TNBC patients. Transcriptomics-based 
subtyping of TNBC into six classes highlights the heterogeneity within 
the TNBC diseases, but it is unclear how the transcriptomics-based 
subtypes link to effective therapeutic strategies, resulting in a poor 
clinical prognosis in comparison to other breast cancer subtypes. Hence, 
there is an imminent need for identifying molecular markers and 
druggable targets against TNBC.  
 
This study is focused on the establishment of functional profiling of 
TNBC cell lines based on their drug vulnerabilities, and to identify novel 
druggable signaling nodes. We studied a panel of 16 TNBC cell lines 
using a functional profiling approach in which we measured the 
responses of TNBC cells to 304 oncology compounds and 355 GSK 
published kinase inhibitors. The clustering analysis based on overall 
drug-responses did not match the transcriptomics-based subtypes, 
suggesting the presence of extensive heterogeneity in TNBC and that the 
genomic or transcriptomic profiles do not always reflect the functional 
behavior of these cells.  
 
First, to go beyond standard anti-proliferative drug effects, we 
established a multiplexed readout for both cell viability and cytotoxicity. 
We identified many drug classes (such as anti-mitotics, anti-
metabolites, mTOR inhibitors), which generally are assumed to have 
cytotoxic effects, mostly exhibited strong effects on cell viability but 
failed to kill the cells. However, in a subset of the cell lines, they induced 
a selective cell death. In those cases, we identified differential levels of 
protein markers linked to the cytotoxic responses (e.g. high level PAI-1 
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linked to anti-mitotics), suggesting their potential use in clinics for 
therapeutic decision. These results highlighted that simple multiplexed 
cell viability and cytotoxicity measurements provide more insight in 
cellular responses towards the treatment and thereby may help in 
providing better translationally predictive readouts. 
 
Second, we devised a novel drug response metric, called normalized 
drug response (NDR), which accounts for many kinds of screening 
artifacts such as signal growth rate differences in positive and negative 
control, as well as in drug-treated conditions. We found that the NDR 
metric is a time-independent method and it significantly improved the 
drug response curve fitting. In addition, the NDR metric allowed us to 
differentiate the drug biology from a single viability readout, and 
enabled classifying the drug effects into four classes: lethal, effective, 
non-effective and growth-stimulatory. Our NDR will be of great value in 
cell-based high throughput drug screening approaches as it cuts down 
the cost and time for the replicate experiments and further validation 
with cytotoxicity assay.  
 
Lastly, we used computational approach to decipher the kinase signal 
addiction of breast cancer cell lines by integrating vulnerabilities to 
kinase inhibitors and their polypharmacology data. We developed the 
kinase inhibition sensitivity score (KISS) to predict single and 
combinatorial signal addictions. For this study, we used 40 approved or 
investigational kinase inhibitors with well-defined target selectivities. 
With this approach, we predicted and validated novel synergistic 
inhibitor combinations against TNBC cells, such as dasatinib with 
axitinib, bosutinib with foretinib or pazopanib, and nintedanib with 
enzastaurin combinations for HCC1937 cells. This study suggests that 
drug sensitivity profiling is a powerful strategy for de-convolving cancer 





J. Michael Bishop and Harold E. Varmus’s concept of genetic alterations 
of oncogenes (activation) and tumor suppressor genes (loss) leading to 
cancer serves as a milestone in cancer biology [1, 2]. The phenomenon 
known as “oncogene addiction” led to the concept of targeted therapy 
[3, 4]. The establishment of the concept that cancer cells cannot survive 
without key oncogenic activities (addictions) led to a huge effort in 
thorough molecular characterization of cancers. Such molecular 
profiling enabled rational design of targeted therapeutics against 
oncogenic addictions (mutations) selective to cancer cells while sparing 
healthy cells. During the past decades, cancer drug discovery has to a 
large extent been focused on developing agents that either inhibit 
oncogenic targets or restore the normal function of tumor suppressors. 
However, cancers often carry multiple genomic alterations that lead to 
rewiring of signaling networks or compensatory pathway activation, 
therefore making it difficult to pinpoint particular oncogenic addictions. 
This calls for the need of alternate strategies to de-convolve cancer 
biology and hence to identify the specific oncogenic addictions/their 
combinations. Moreover, far from all known oncogenic drivers can 
currently be pharmacologically targeted, highlighting the complexity in 
translating oncogenes to effective targeted drugs. For instance, RAS 
mutations are prevalent in 20-25% of all human cancers, yet anti-RAS 
treatments remain as an unmet need.  
 
Cancers harboring undruggable genetic aberrations increases the 
complexity in cancer drug discovery. Extensive ‘omics’ (genomics, 
epigenomics, transcriptomics, proteomics, metabolomics) studies of 
TNBC have already highlighted the heterogeneity and complexity of the 
disease at both the molecular and clinical levels. The primary therapy is 
limited to surgery, radiotherapy and cytotoxic chemotherapy and there 
is therefore an unmet demand for effective targeted therapy against 
TNBC. However, the heterogeneity of the disease argues that no single 
solution will be found. This highlights a need for a 
precision/personalized therapy stratification based 0n additional 
functional profiling of cancer. The accessibility of a broad range of 
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molecularly targeted and selectivity-profiled drugs creates an 
unprecedented opportunity to establish a drug sensitivity-based 
functional profiling of cancers, with the aim to establish functional 
disease stratification and novel therapeutic strategies. Furthermore, the 
availability of an increasing number of approved and investigational 
oncological drugs offers a unique possibility for rapid clinical 
translation of findings generated from the functional studies.  
 
Most solid tumors are therapeutically challenging not only due to the 
lack of targeted therapies but also because of the development of 
resistance to targeted monotherapies. Monotherapies are proven to 
generally be inadequate because of rapid development of de novo or 
acquired drug resistance arguing for the establishment of precision drug 
combination strategies to efficiently target the cancer cells [5, 6]. 
However, defining effective drug combinations upfront is often 
challenging, and due to increasing number of targeted compounds, 
testing all potential combinations is experimentally challenging [7] and 
expensive even in a high throughput setting. Therefore, computational 
systems approaches are required to recognize the potential drug 
combinations. An integrated systems biology approach, which 
incorporates drug sensitivity data, drug activity profiles and cancer 
signaling networks could establish a more profound understanding of 
cancer biology and novel stratified therapeutic strategies. 
 
In cell-based chemical screening approaches, quantification of drug 
responses is crucial to define drug vulnerabilities, in terms of both 
efficacy and selectivity. Traditionally, end-point viability or toxicity 
measurement assays are used to characterize the drug-induced effects in 
cell line screens. Percent inhibition (PI) is a normalization metric, which 
is used to delineate the effect of individual dose response data by 
normalizing the values between positive and negative controls. 
However, such an end point normalization metric suffers heavily from 
experimental limitations, because it disregards the experimental aspects 
such as cell growth rate, seeding discrepancies, and cell-health 
measurement assay artifacts both in control conditions and under drug 
treatments. This has raised a debate about inconsistency in drug 
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screening results and the question of how to enhance the reproducibility 
in cancer cell drug screening. 
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Review of the literature 
 
1. Breast cancer 
 
The rate of breast cancer mortality has fallen dramatically since the 
1980s because of refined drug regimens (hormonal and targeted 
therapies) along with technological advancement in breast cancer 
screening (mammography, MRI, among others) making it possible to 
both diagnose and effectively treat at an early stage of disease[8]. Still, 
breast cancer is the second leading cause of cancer death in women 
worldwide, only outnumbered by lung cancer. According to 
GLOBOCAN2012, breast cancer accounts for 25% of newly diagnosed 
cases of all cancer in women, claiming the lives of ~522,000 women 
worldwide each year [9]. Almost 5% of breast cancers are considered as 
familial, where BRCA1 and BRCA2 genes mutations are the most 
commonly mutated inherited genes linking to the disease [10-12]. 
Women with germline mutations in BRCA1 have a lifetime breast cancer 
development risk of 55-65% whereas the same number for germline 
with BRCA2 mutations is 45% [13]. Still, somatic mutations are 
perceived as the most common causes of breast cancer. Alterations in 
TP53, RB1, GATA3, PTEN, PI3CA, CCND1, FGFR1, MYC, MAP3K1, and 
ERBB2 are the ten most prevalent somatic genetic events driving breast 
cancer [14].  
 
Even though breast cancer by its name is a single disease, it is highly 
heterogeneous and can be histologically differentiated into 21 subtypes 
and molecularly into at least four subtypes, which vary in tissue 
morphology, treatment susceptibility, prognosis and risk assessment 
[15-20].  
 
1.1. Breast cancer subtypes 
 
The routinely used subtypes of breast cancer in clinical practice are 
categorized based on the profiles of three immunohistochemistry 
markers: hormonal receptors (estrogen and progesterone receptors), 
13 
human epidermal growth factor receptor 2 (HER2/ERBB2) and a cell 
proliferation marker Ki67 [18, 21]. Based on receptor levels, breast 
cancer is divided into 4 molecular subtypes: luminal A, luminal B, 
HER2 enriched and triple negative (figure 1).  
 
 
Figure 1: Classification of breast cancer based on receptor level [22]. Pie slice sizes 
represent fractions of total numbers of breast cancer cases. 
1.1.1. Luminal A 
 
Luminal A type of breast cancers express estrogen receptor (ER) and/or 
progesterone receptor (PR) but lack HER2 amplification (HER2-). They 
account for about 70% of total breast cancer. They have the most 
favorable prognosis among the major breast cancer subtypes since they 
are relatively slow growing and less aggressive. 
 
1.1.2. Luminal B 
 
In addition to estrogen and progesterone receptors, luminal B type 
breast cancers also overexpress HER2 (HER2+) and their prevalence is 
about 10% of the total cases. The luminal B subtype is regarded as more 
aggressive than luminal A. Luminal B breast cancers also express high 
levels of Ki67 protein, indicating a large population of actively 
proliferating cells [23]. 
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1.1.3. HER2 enriched  
 
This is a subtype that accounts for about 4% of breast cancers. HER2 
enriched breast cancers have amplified HER2 expression but lack the 
expression of both hormonal receptors (HR). They tend to be more 
aggressive than HR+ breast cancers and HER2 enriched breast cancer 
patients therefore have poorer prognosis than patients with luminal 
subtypes [24].  
 
1.1.4. Triple negative  
 
As the name indicates, tripe negative breast cancers (TNBC) lack both 
estrogen and progesterone hormonal receptor expression and HER2 
amplification. They are the most aggressive and recurring type of breast 
cancers with the poorest prognosis of all [25-28].  TNBC is often 
confused or restricted to basal subtype, because of high rates of overlap 
in molecular signature between TNBC and basal breast cancer subtype 
(~70%)[29]. In addition to lack of ER, PR and HER2 as in TNBC, basal 
breast cancers also often exhibit enhanced expression of EGFR and 
cytokeratin 5/6 [30]. TNBC is described in more detail in section 1.3. 
 
1.2. Breast cancer therapy options 
 
Breast cancer treatment options depends on several factors: stage, 
grade, type, menopausal state, among others. The stage of cancer is 
defined by the size and extent of its metastasis, where higher stage 
numbers indicate greater extent of metastasis and poorer prognosis. 
The grade, unlike the stage, only defines the extent of cell 
differentiation, where higher grades indicate gradually poorer 
differentiation. Most patients go through surgery (stage I-III); tumor 
excision (lumpectomy) or whole breast removal (mastectomy). Surgery 
is mostly followed by adjuvant therapy to avoid relapse of the disease. 
The adjuvant therapies given to the patients are usually radiotherapy, 
cytotoxic chemicals (e.g. doxorubicin, cyclophosphamide, docetaxel), 
hormonal therapy (e.g. tamoxifen and raloxifene), and growth factor 
targeted therapy (e.g. trastuzumab and lapatinib). The outcome of the 
treatment depends on the disease stage. The 5-year survival rate of 
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breast cancer patients drops dramatically from almost 100% for stage I 
patients to 22% for stage IV patients. Stage II patients have a 5-year 
survival of 93% and stage III have 72% [31, 32].  
 
As a first line of therapy, hormone receptor positive (HR+) breast 
cancer patients are given hormonal therapies, which include selective 
estrogen receptor modulators (SERMs), such as tamoxifen; selective 
estrogen receptor degrader (SERDs) like fulvestrant; aromatase 
inhibitors, like anastrozole, which blocks the production of estrogen. 
Alternatively, luteinizing hormone-releasing hormone (LHRH) 
antagonist goserelin is also efficacious in treating HR+ breast cancer 
[33]. Administration of tamoxifen to ER+ breast cancer patients has 
resulted in a 39% reduction in recurrence rate averaged over all time 
periods and around 45-50% reduction in mortality rate throughout the 
first 15 years [34, 35]. For HER2 amplified breast cancer patients, 
humanized monoclonal antibodies against HER2 such as trastuzumab 
and pertuzumab form the first-line of therapy [36]. Enhanced disease-
free survival and overall survival are observed with anti-HER2 therapies 
in HER2 amplified breast cancer patients [37]. 
 






Devoid of hormonal receptors and HER2 amplification, TNBC still 
remains a therapeutic challenge as neither hormonal nor anti-HER2 
therapy have any effect on it. To date, the therapy against TNBC is 
limited to conventional cytotoxic chemotherapies, which highlights the 
imminent need to establish targeted therapy for TNBC management. 
 
1.3. Triple Negative Breast Cancer  
 
TNBC is a highly aggressive subtype of breast cancer, which accounts 
for 15-20% of breast cancer cases and exhibits the poorest prognosis 
among all the breast cancer subtypes [38]. The 5-year survival rate of 
TNBC patients is significantly low, 77% as compared to 93% in non-
TNBC patients [39]. TNBC tumors are larger in size, usually grade II-III 
and lymph node positive [27]. They also have higher rate of distant 
recurrence/metastasis to brain and lungs, but less likely to bones [27, 
40]. At molecular level, most TNBC tumors exhibit myoepithelial/basal 
markers such as increased expression of EGFR, cytokeratins (CK5, CK6, 
CK14, CK17) and KIT [41]. The most recurrent genetic aberrations in 
TNBC are loss of TP53, RB1 and BRCA1/2, along with activating 
mutations in the PI3K pathway, loss of PTEN or INPP4B and 
amplification of MCL1 and MYC [17, 42]. Around 20% of TNBC patients 
also harbor BRCA1/2 germline mutations, whereas additional 
downregulation of BRCA1/2 in TNBC is also associated with epigenetic 
alterations and overexpression of negative regulators of the BRCA1 
promoter (like Id4) [43-46].   
 
TNBC is a highly heterogeneous breast cancer subtype. Lack of the 
identification of common oncogenic driver alterations has made it 
highly challenging for the development of targeted therapy. To address 
this challenge, several studies have been carried out to classify TNBC 
cases into subtypes based on their molecular profiles. While comparing 
the overall gene expression profile (7,770 genes) of 97 TNBC samples, 
Kreike et al. divided them into five subgroups [25]. Similarly, Lehmann 
et al. classified TNBC into seven subgroups based on genome-wide gene 
expression profiling (six defined classes and one undefined), which 
exhibit distinct transcriptomic signatures: two basal subtypes (BL1 and 
BL2), two mesenchymal subtypes (M and MSL), an  
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immunomodulatory (IM) subtype, and a luminal androgen receptor 
positive (LAR) subtype [47]. In a recent study, Burstein et al. also 
established a similar classification schema of TNBC by analyzing the 
genomic and transcriptomic profiles of 198 tumors, in which they 
defined four subtypes; basal-like/immune-suppressed (BLIS), basal-
like/immune activated (BLIA), mesenchymal (MES), and 
luminal/androgen receptor (LAR) [48]. Elsawaf et al. assigned four 
subtypes based on expression of 13 biomarkers (BCL2, CK7, CK14, 
CK18, CK19, CK56, CD117, EGFR, Ki67, p16, p53, vimentin, WT1); two 




Figure 2: Molecular classification of TNBC. A) Subgrouping of TNBC into 4 groups based 
on expression level of 13 biomarkers [49], highlighted are expression level of respective 
biomarkers. B) Subtyping of TNBC into 5 groups based on the Kreike et al. study [25]. 
Group IV and V do not have any unique markers. C) Overlap between TNBC subtypes 
based on the Burstein et al. and Lehmann et al. studies [47, 48].  
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Several other studies have reported clustering of TNBC based on the 
expression of specific markers. For example, a subgroup lacking cell-cell 
tight junction protein claudin was defined as “claudin-low” and a 
subgroup enriched in immune marker interferon as “interferon-rich” 
[50, 51]. However, the classification schema defined by Lehmann et al. 
is widely accepted since the subgroups exhibit particular gene 
expression signatures, and in vitro studies in TNBC cell lines hint that 
these subtypes also differ in their response towards drugs targeting 
specific driver signaling pathways [47].  
 
1.3.1. Basal like 1 (BL1) subtype 
 
The BL1 subtype has an enriched gene profile related to cell cycle and 
cell division pathways evident with high expression of proliferation 
markers such as AURKA, AURKB, TTK, MYC, PLK1, BIRC5, CENPA, 
CENPF, BUB1, CCNA2, PRC1, NRAS, MKI67. They are also heavily 
enriched in the expression of DNA damage response 
pathways/components including CHEK1, MDC1, RAD, FANCA, FANCG, 
RAD51, RAD21, RAD54BP, NBN, EXO1, MSH2, MCM10.  
 
1.3.2. Basal like 2 (BL2) subtype 
 
The transcriptomic profile of the BL2 subtype is enriched for growth 
factor signaling components such as EGFR, IGFR, NGF, MET and 
Wnt/β-catenin pathways. Additionally, BL2 is also enriched for 
glycolysis and gluconeogenesis pathways. As the BL2 subtype TNBCs 
express TP63 and MME (CD10), they are regarded to be of 
myoepithelial tissue origin.  
 
1.3.3. Immuno-modulators (IM) subtype 
 
The IM subtype has enriched immune cell response gene signatures. 
These include IRF1, IRF7, IRF8, ITK, JAK1, JAK2, STAT1, STAT4, 




1.3.4. Mesenchymal (M) subtype 
 
The M subtype has enriched gene expression related to cell motility 
(Rho pathway), cell-differentiation (TGF-β/SMAD, Wnt/β-catenin and 
ALK pathways) and extracellular matrix (ECM) receptor interactions.  
 
1.3.5. Mesenchymal stem like (MSL) subtype 
 
The MSL subtype share gene ontologies for several biological processes 
with the M subtype, such as cell motility, growth and differentiation 
pathways. However, the MSL subtype is different from M since it also 
includes stem cell markers such as ABCB1, ABCA8, ALDHA1, BCL2, 
BMP2, PROCR, HOXA5, HOXA10, MEIS1, MEIS2, MSX, MEOX1, 
MEOX2, BMP2, ENG, KDR, NGFR, VCAM1. The MSL subtype is also 
highly enriched for genes associated with growth factor signaling such 
as EGFR, PDGFR, calcium signaling, inositol phosphate metabolism, 
ERK1/2 signaling, G-protein coupled receptor signaling, ABC 
transporter, adipocytokine signaling and angiogenesis (KDR, TEK, TIE, 
EPSA1).  
 
1.3.6. Luminal Androgen Receptor (LAR) subtype 
 
The LAR subtype has a gene expression profile enriched in hormonally 
regulated pathways including steroid synthesis and estrogen 
metabolism, which include AR, DHCR24, ALCAM, FASN, FGFR4, 
FKBP5, SPEDF, APOD, PIP, CLON8. 
 
1.4. TNBC therapy: current status and future trends  
 
Despite the extensive molecular profiling, no single targeted TNBC 
therapy is yet established. The lack of targeted therapies limits the 
treatment options to traditional cytotoxic chemotherapy, radiation and 
surgery, which are curative only to a fraction of TNBC patients. The 
first-line therapy includes anthracyclines (doxorubicin, epirubicin), 
microtubule inhibitors (paclitaxel, docetaxel, vinorelbine, eribulin, 
ixabepilone), antimetabolites (capecitabine), cyclophosphamide and 
platinum compounds (carboplatin, cisplatin), mostly given in 
20 
combinations [52, 53]. Masuda et. al. compared pathologic complete 
response (pCR) rate among 132 patients treated with neoadjuvant 
chemotherapies (paclitaxel, doxorubicin and cyclophosphamide) [54] 
and observed that BL1 patients demonstrate highest pCR rate (52%) 
followed by MSL (23%) and LAR (10%). BL2 had the lowest response 
rate (0%) [54]. The mitotic inhibitors seem to be effective only in the 
subgroup of patients exhibiting high proliferation rates and impaired 
DNA repair machinery. Such different pCR rates in different TNBC 
subgroups strongly argue for the need of further patient stratification 
and precision medicine for TNBC.  
 
Several targeted therapies are being investigated in the clinic, exploiting 
the potential molecular targets incurred from TNBC expression 
signature [55]. Few of the clinical trials are run with molecular inclusion 
criteria (precision approach), where only those patients that exhibit the 
defined molecular signature (or markers) qualify for the treatment. For 
example, several Poly-ADP ribose polymerase (PARP) inhibitors (e.g. 
olaparib, (ClinicalTrials.gov identifiers: NCT026815562, 
NCT03205761); veliparib, (NCT02849496); talazoparib, 
(NCT02401347); and rucaparib (NCT01074970)) are currently active in 
late phase clinical studies, mostly against BRCA mutation carriers as 
PARP inhibitors appeared to be highly effective against BRCA mutant 
TNBC [55, 56]. Similarly, the checkpoint kinase 1 (CHK1) inhibitor 
prexasertib is being investigated (phase II, NTC02203513) against 
BRCA1/2 mutant metastatic TNBC patients. A phase II basket trial is 
being carried out with the CDK4/6 inhibitor ribociclib against CDK4/6 
pathway activated tumors, including TNBCs (NCT02187783).  
 
Anti-androgen agents, such as bicalutamide, enzalutamide, enobosarm, 
seviteronel, are in early clinical studies against AR+ TNBCs [55]. The 
androgen receptor (AR) signaling enriched subtype LAR also exhibit 
high rate of PIK3CA (the gene encoding the PI3Kα protein) activating 
mutations, which make both AR and PI3K potential targets against AR+ 
TNBCs. The combination of androgen antagonists and PI3K inhibitors 
has been reported to yield additive inhibitory effect on tumor growth 
against TNBC [57]. Currently, the combination of the PI3K inhibitor 
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taselisib and the anti-androgen enzalutamide is being evaluated in a 
phase II clinical trial against AR+ TNBCs (NCT02457910).  
 
An interim analysis of the on-going I-SPY2 (novel personalized clinical 
trial) phase II trial (NCT01042379, expected to be completed by 
December 2018) has estimated that the combination of veliparib and 
carboplatin will enhance pCR in TNBC patients (51%) compared to the 
control arm treated with standard neoadjuvant therapy only (26%), and 
based in an interim analysis, the combination has been estimated 88% 
likely to be successful in a phase III trial [58].  
 
On the other hand, most of the targeted therapies that are currently 
active in clinical studies against TNBC are without any molecular 
inclusion criteria. For example, another cyclin dependent kinase 4/6 
(CDK4/6) inhibitor trilaciclib, is being investigated in phase II clinical 
trials against TNBCs (NCT02978716). Apoptosis inducing agent 
selinexor is being assessed in a phase II trial for metastatic TNBC 
(NCT02402764). DNA methyltransferase and histone deacetylase 
(HDAC) inhibitors have been reported to reverse the epithelial to 
mesenchymal transition (EMT) process and hence inhibit the tumor 
initiating cells in TNBC. Therefore, the HDAC inhibitor entinostat is 
currently being explored in clinical trials (e.g. NCT02708680) [59]. 
HSP90, an important molecular chaperone known to stabilize various 
growth factor receptors (EGFR, VEGFR) and mutant oncoproteins (p53, 
PI3K, AKT), is regarded as a potential target for TNBC [60, 61]. The 
HSP90 inhibitor onalespib is currently under clinical evaluation for 
TNBC (NCT02474173). 
 
Receptor tyrosine kinases (RTK) and signal transduction pathway 
components play a vital role in cell proliferation, differentiation, 
metabolism, cell survival and apoptosis, making them important targets 
for cancer treatment. There are several RTK inhibitors and other signal 
transduction kinase inhibitors explored in different level of clinical 
trials against TNBC [55]. Even though these protein kinase inhibitors 
have shown great results in in vitro or preclinical models, they have not 
been very successful in clinic as single agents due to cellular 
reprogramming and rapid development of resistance. One of the best 
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examples is the failure of EGFR inhibitor (cetuximab) in the clinic 
against TNBC in spite of the high prevalence (~70%) of overexpressed 
EGFR in TNBC. It was later discovered that inhibition of EGFR leads to 
the activation of compensatory AKT and ERBB3 signaling pathways, 
which ultimately mediates resistance [62]. A phase I study of pan-EGFR 
family inhibitor neratinib combined with mTORC1 inhibitor 
temsirolimus resulted in synergistic anti-tumor activity [63].  The 
observed anti-tumor activity may be due to polypharmacology effect of 
neratinib as it is expected to not only block EGFR signaling but also the 
compensatory ERBB3 signaling pathways. This rather urges for the use 
of drugs with multi-targets (or combination therapy), which lead to 
concurrent blockage of the compensatory signaling pathways. The 
current clinical trials of protein kinase inhibitors are mostly assessed 
along with conventional chemotherapies or compensatory pathway 
inhibitors.   
 
A number of agents targeting angiogenesis, one of the hallmarks of 
cancer, (e.g. bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) are 
already approved for clinical use against various cancers, but not TNBC. 
Several anti-angiogenic therapies targeting VEGFR (bevacizumab, 
NCT01898177; sorafenib, NCT02624700; apatinib, NCT03243838; 
cediranib, NCT01116648) are currently being explored against TNBC in 
clinical settings [55]. However, the effects of anti-angiogenic therapies 
against TNBC are debatable as they have failed to show clinical 
significance in the past [64-66]. It is rather shown that anti-angiogenic 
treatment enhances invasion and vasculogenic mimicry in TNBC [67].   
 
Tumor infiltrating lymphocytes (TILs) and immunotherapy against 
cancer (immune oncology) have gained tremendous attention in recent 
years [68-70]. The subtype of TNBC defined by enhanced expression of 
genes involved in different immune pathways like T-cell signaling, 
antigen processing, interleukin pathways, cytotoxic T-lymphocyte 
antigen 4 (CTLA4) pathways, among others advocate the potential of 
using immune oncology agents against TNBCs [47, 71]. TNBC is 
reported to have high level of TILs, suggesting the potential of immune 
oncology therapy against it [72]. Several immune checkpoint inhibitors 
are currently being clinically investigated against TNBCs, specifically 
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CTL4A inhibitors (ipilimumab), and programmed cell death 1 (PD-
1)/PD-1 ligand (PD-L1) inhibitors (atezolizumab, pembrolizumab, 
nivolumab, durvalumab, PDR001). For example, in a phase I study of 
atezolizumab for metastatic TNBC patients, responders (10-13%) had a 
long-lasting benefit [73]. Currently atezolizumab in combination 
paclitaxel is being tested in a phase III clinical trial against metastatic 
TNBC (NCT03125902).  
 
In summary, even today, most clinical trials against TNBCs are carried 
out in randomized fashion, treating them as a single disease. Since 
TNBC is such a heterogeneous subtype of breast cancer, treating it as a 
single disease may not be the best approach. It is already alarming as we 
have witnessed a plethora of targeted agents showing high potency in 
preclinical studies but fail in the randomized trials. Therefore, this calls 
for further patient stratification, umbrella trials (trials with molecular 
inclusion criteria) and tailored treatment strategies to establish effective 
therapeutics against TNBC.  
 
2. Precision medicine approach for TNBC  
 
Unlike the general “one drug – one disease” philosophy for cancer 
therapeutic development, precision medicine refers to tailored or 
stratified treatment based on different molecular and pathological traits 
exhibited by a particular individual or group of patients suffering from a 
particular disease. Cancer is one of the most heterogeneous types of 
disease marked by both molecular and clinical differences. Even 
patients suffering from same type of cancer exhibit different genetic and 
epigenetic makeups and molecular characteristics. This makes it highly 
unlikely to discover a golden bullet that cures all the patients in most 
cancer forms. Therefore, there is a need for developing stratified 
therapeutic options. For this, sub-classification of the disease based on 
its unique molecular characteristics and subsequent tailored 
therapeutics against the respective subgroup is expected to aid to 




The main advantages of precision/personalized medicine can be 
summarized in two points: 
1. Establishing effective targeted therapy directed towards specific 
tumor pathology or specific signaling pathways along with 
patient stratification.  
2. Avoiding unnecessary treatments, hence minimizing the risks of 
side-effects as well as the cost of ineffective or adverse 
treatments.  
 
Recently, precision medicine has gained enormous attention boosted by 
readily assessable sequencing technologies and existing success stories 
of stratified therapy against different driver mutations; for example, 
targeting the fusion gene BCR-ABL1 in chronic myeloid leukemia, the 
EML4-ALK fusion or mutant EGFR in non-small-cell lung cancer, and 
mutant BRAF in melanoma, which significantly extended survival the 
respective disease patients [74-76]. Breast cancer therapy in general is 
one of the best examples of precision medicine, which changed the 
paradigm for treatment of cancer. In fact, the history of precision 
medicine in breast cancer dates back to sixties, far before the human 
genome project, which gave rise to anti-hormonal therapy (anti-
estrogen) directed against the HR-positive patients. This was 
established solely based on tissue histopathology (receptor level). Even 
now the anti-estrogen treatment is guided by molecular markers rather 
than genetic markers since genomics fails to capture this driver 
abnormality. Patient stratification and receptor status based therapy 
has significantly improved the prognosis of receptor positive breast 
cancers. The best example is estrogen receptor antagonists (e.g. 
tamoxifen, the first successful precision therapy in cancer), which 
significantly reduced the mortality rate and reoccurrence of the disease 
in hormone receptor positive breast cancer patients [34, 77, 78]. 
Similarly, anti-HER2 therapies (e.g. trastuzumab), increased both 
progress-free survival and overall survival rate of HER2-positive breast 
cancer patients [79-81]. Another example of phenotypic-based precision 
medicine exhibiting considerable impact in clinics is the use of anti-
androgen therapy against prostate cancer. These clinical outcomes 
revolutionized the field of modern precision medicine. 
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Large studies on cancer cell lines (covering different tissue types, some 
specific to TNBC) using genomics, transcriptomics, proteomics, 
epigenomics and extensive functional profiling based on drug sensitivity 
and loss-of-function phenotypes have been carried out in an attempt to 
understand the disease in detail and to establish tailored treatment 
strategies [82-92]. Even though it has become possible to favorably 
treat receptor-positive breast cancers, TNBC still poses a challenge for 
clinical treatment and management. Despite extensive molecular 
profiling of TNBC, the key genetic events driving the disease are still 
unclear. Different molecular subtyping approaches have not yet yielded 
any targeted therapy against TNBC and also, the drug response 
prediction power of such molecular subtypes is relatively poor except 
for immune enriched or LAR subtypes [25, 93]. This argues for the need 
of drug sensitivity based phenotypic profiling of TNBC to establish 
actionable subtypes. Further phenotypic profiles can be matched with 
molecular/genetic signatures to establish phenotypic subgroup-specific 
biomarkers for patient stratification against the particular treatment 
option. Rather than putting patients in a single group while performing 
clinical trials, which is mostly the case in TNBC, biomarker based 
patient stratification and biomarker-driven trials should be 
implemented. 
 
3. Drug sensitivity testing for precision medicine 
 
The availability of approved and investigational compounds active 
against a wide range of biological targets provides an unprecedented 
opportunity in drug repositioning studies [94, 95]. Chemical 
perturbation screens employing broadly targeted compound libraries 
could allow us to identify individualized novel drug vulnerabilities that 
go beyond the prediction of current genomic analysis and that can 
readily be translated to clinics [94, 96]. In addition, it may also help to 
identify and establish novel drug-target interactions with clinical 
application [95].  
 
As we have realized that any given single anticancer therapy is likely to 
be effective only in a subset of patients, in vitro/ex vivo drug 
vulnerability testing holds promises in predicting drug efficacy 
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addressing the heterogeneity and genomic complexity of human cancers 
[95, 97, 98]. The establishment of the first of its kind, the National 
Cancer Institute 60 cell line (NCI60) platform [82] revolutionized the 
high-throughput cancer cell line screening approach in drug discovery. 
In the seminal study, 60 distinct cell lines representing 9 different 
tumor types were screened against a panel of anticancer compounds. 
Later on, it was realized that use of only 60 cell lines was not enough for 
capturing genetic and phenotypic diversity, heterogeneity and 
responders to low-frequency targeted therapies [98]. Thus, more recent 
studies like the Cancer Genome Project (CGP) [99] and Cancer Cell Line 
Encyclopedia [13] [83] have expanded the cell line panel to several 
hundreds. Specifically, CGP included 727 cell lines representing 16 
tumor types screened against 138 drugs, whereas CCLE included 947 
cell lines representing 36 tumor types screened against 24 drugs. Along 
with the drug vulnerability data, they also compared the genomic 
profiles of the cell lines for the establishment of biomarkers as 
predictors of therapeutic intervention. However, with such pan-cancer 
approaches there has been minimal success in establishing novel 
predictive biomarkers, which are limited to well-known oncogenic 
drivers. This therefore calls for cancer type/subtype specific precision 
medicine approaches rather than pan-cancer studies.  
 
Studies on well-characterized HER2-positive breast cancer cell lines 
with anti-HER2 compounds have revealed the potential of drug 
screening approaches in establishing the association between drug 
sensitivity and activated signaling pathway or molecular subtypes [100, 
101]. Similarly, in a larger scale study led by Gray and Spellman, where 
45 different breast cancer cell lines representing different 
transcriptional subtype of breast cancer were tested against 77 different 
approved/investigational drugs, they were able to establish subtype 
specific drug responses [102]. For example, they found that basal cell 
lines expressing upregulated DNA-damage response proteins were 
selectively sensitive to cisplatin, whereas ERBB2 amplified cell lines had 
increased HSP90 expression and responded to geldanamycin, an 
HSP90 inhibitor. This advocates the usefulness of screening larger 
panels of tumor cell lines that incorporates different subtypes of the 
specific tumor. This will help to further decipher the subtype-related 
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molecular pattern and establish precision therapeutics against the 
disease.  
 
In general, four factors play a major role in successful use of drug 
sensitivity screening to identify phenotypic cancer vulnerabilities: 
1. selection of cell line panel  
2. selection of compound library  
3. selection of cell health measurement system and  
4. drug response quantification technique  
 
3.1. Cell line panel  
 
It is already evident that cancer is a heterogeneous group of diseases 
exhibiting diverse tissues of origin, morphology, phenotype and clinical 
responses. Hence, the cell line screen-based drug positioning approach 
should try to include a larger panel of cell lines, which incorporates all 
representative subtypes of a particular cancer. Incorporating various 
kinds of morphologically, physiologically and genetically divergent cell 
lines in the analysis will provide a power in predicting therapeutic 
outcome in relation to its molecular pattern. However, the challenge 
here is to come up with optimal/critical number of cell lines upfront. 
For example, even if we take large-scale screening studies like CCLE and 
CGP, the number of cell lines are generally modest when it comes to 
individual cancer types. Rather than such pan-cancer approaches, 
analysis on collections of as highly diverse cell lines as possible from an 
individual cancer type is expected to give greater insight into the 
disease. 
 
3.2. Compound library 
 
It is crucial to have an unbiased compound collection, representing 
myriad of drug mechanisms of action, to identify and establish cell line 
selective signaling node vulnerabilities as well as non-specific 
cytotoxics. One of the limitations realized later for the seminal NCI60 
study was the use of generic cytotoxics in the screens as they have 
higher rate of response, making it difficult to differentiate tissue/sub-
type selective response or tumor heterogeneity [98]. Later, the 
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compound collection was expanded, currently it consists of an array of 
chemical compounds and natural products ranging from nonspecific 
cytotoxic agents to targeted therapies. With the promises of targeted 
therapy to establish clinically applicable context specific treatments, all 
subsequent big drug screening studies has focused more on the targeted 
therapies. Barretina et. al. studied the effect of 24 targeted oncology 
compounds across 479 cell lines, where the tested compounds were 
mostly tyrosine kinase inhibitors [83].  
 
The increasing number of well-characterized pharmacologically active 
approved and investigational compounds allows the identification and 
establishment of new readily translatable drug repurposing paradigms. 
Therefore, the use of approved and investigational anticancer 
compounds in the screens is common nowadays. Daemen et al profiled 
70 breast cancer cell lines with 90 approved or experimental 
compounds to predict the drug sensitivities based on the molecular 
profiles of the cell lines [85]. Small molecule probes with selective 
molecular targets can serve as tool compounds to find novel druggable 
molecular target addictions (dependencies for cell survival) as well as to 
cross validate the selective molecular mechanisms for cancer cell 
vulnerabilities [103]. Inactive pro-drugs, which only get activated 
(metabolized) within the body (specific to tissue, organ or systemic 
fluids), allow us to target specific tissue and reduce adverse effects 
[104]. However, since these pro-drugs are limited to specific body 
metabolism, active metabolites that mimic the pro-drugs in in vitro 
settings are required. The big drug screening approaches like Genomic 
of Drug Sensitivity in Cancer (GDSC) [89, 105] and Therapeutic 
Response Portal (CTRP v2) [106] compiled their compound library with 
anticancer approved, experimental and tool compounds incorporating 
both cytotoxic and targeted agents.  
 
In a recent study carried out by Licciardello et al, a collection of FDA 
approved clinical compounds (308 biochemically diverse compounds), 
which also includes non-oncology therapeutic agents, called the CeMM 
Library of Unique Drugs (CLOUD) was used to screen prostate cancer 
cell lines [107]. Combination screens of CLOUD compounds were 
performed to identify the synergistic drug combinations that result in 
29 
reduction of prostate cancer cell viability. They were able to establish a 
novel synergistic combination (the antiandrogen flutamide and the 
vitamin K antagonist phenprocoumon) that is effective against 
androgen receptor (AR) mutant prostate cancer [107]. This highlights 
the need of widening the target space beyond known oncology targets. 
Thus, a prudent approach to build a comprehensive compound library 
collection for anti-cancer activity screens should be to include 
pharmacologically active compounds with known bioactivities (target 
inhibition profile) and well-characterized target space. Moreover, 
compounds with similar mode of actions should also ideally cover 
structural diversity to cross-validate the mechanisms of action. 
 
3.2.1. Kinase inhibitors 
 
Due to their pivotal role in cellular functioning, kinases are one of the 
most attractive oncology therapeutic target classes [108]. Protein 
kinases are the enzymes that modify other proteins by transferring a 
phosphate group from ATP (mostly) to amino acids with a free hydroxyl 
group (most often serine, threonine or tyrosine). They play key roles in 
signal transduction and regulate a vast range of cellular activities 
including metabolism, immune regulation, and survival. Besides, many 
protein kinases can act as oncogenes [109, 110], most common are 
hyperactivation of protein tyrosine kinases (EGFR, ERBB2, FGFR, JAK, 
ABL, ALK, RET, KIT, etc.) and the PI3K lipid kinases and their 
downstream protein kinases like AKT, mTOR, and p70S6K. Therefore, 
due to their tremendous therapeutic potential and “druggability”, 
protein kinases are the most heavily targeted target proteins in oncology 
drug discovery. Most kinase inhibitors target the highly conserved ATP-
binding pocket of the catalytic domain which can result in inhibitor 
promiscuity [111]. Such promiscuity leads to a polypharmacology effect, 
which often can lead to a detrimental clinical outcome when inhibition 
of unwanted (off-target) kinases occurs, resulting in reduced efficacy or 
loss of therapeutic windows, but can in some cases also improve clinical 
efficacy if they target compensatory pathways [112].  
 
Over the past two decades, protein kinases have been intensively 
investigated as targets to treat neoplastic diseases. The potential of 
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kinase inhibitors was first evident when trastuzumab (Herceptin), a 
monoclonal antibody against HER2 was approved for HER2-positive 
breast cancer in 1998. In 2001, first small molecule kinase inhibitor 
(SMKI) was approved for use in cancer; the BCR-ABL inhibitor imatinib 
(Gleevec) against chronic myeloid leukemia (CML), which directed the 
investigation massively towards SMKIs. To date, 45 drugs targeting 
kinases have been approved as cancer therapeutics; 39 SMKIs and 6 
monoclonal antibodies (Figure 3), along with hundreds of inhibitors 
that are currently being explored in clinical trials [113-116]. Five SMKIs 
have been approved for treatment of advanced stage breast cancer; the 
two HER2 inhibitors lapatinib (Tykerb) and neratinib (Nerlynx), the 
three CDK4/6 inhibitors palbociclib (Ibrance), ribociclib (Kisqali) and 
abemaciclib (Verzenio) and the allosteric mTORC1 inhibitor everolimus 
(Afinitor). Similarly, two monoclonal antibodies targeting HER2 have 
been approved for breast cancer treatment, trastuzumab (Herceptin) 
and pertuzumab (Perjeta). An antibody-drug conjugate ado-
trastuzumab emtansine (Kadcyla) is approved for treatment of 
trastuzumab resistance breast cancer patients. All these were approved 
for HER2-positive breast cancer except everolimus, palbociclib, 
ribociclib and abemaciclib, which have been approved for hormone-
receptor positive, HER2-negative breast cancer [117-122]. 
 
The protein kinases can be broadly divided into seven major kinase 
groups based on sequence similarity (highlighted in bold) as follows:  
TK, tyrosine-kinase; TKL, tyrosine kinase-like; STE, homologs of yeast 
Sterile 7, Sterile 11, Sterile 20 kinase; CK1, casein kinase ; AGC, protein 
kinase A, protein kinase G, and protein kinase C containing families; 
CAMK, calcium/calmodulin-dependent protein kinase; CMGC, cyclin 
dependent kinase, mitogen-act protein kinase, glycogen synthase kinase 
3, and dual specificity protein kinase CLK containing families. Beside 
these, there are three other kinase classes, which exhibit structural 
similarity to protein kinases, including lipid kinases PI3K; atypical, 
ABC1, Alpha, Brd, PDHK, PIKK, RIO, TIF1 containing families; and 
others containing families that do not fall in any of the mentioned 
families. Out of 518 enzymatically active human protein kinases, 299 
have been proposed as potential therapeutic targets and more than 
70 000 structurally unique compounds targeting them are currently 
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described [113, 123]. Even though extensive studies are being held to 
target the kinome, clinically active drugs are limited to only a small 
subset of human kinases, mostly TK, CMGC and PI3K kinases, 
neglecting a large set of kinome (Figure 4). This emphasizes the 
necessity of exploring kinases of other classes, which might hold equal 
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Figure 3: Summary of clinically approved kinase inhibitors, by their year of initial 
approval. Small molecule inhibitors are shown in blue and kinase-targeted monoclonal 
antibodies are shown in red. (fda.gov, ema.europa.eu/ema/) 
 
To explore the neglected kinases targets, researchers at 
GlaxoSmithKline (GSK) generated a compound collection, which has a 
broad kinome coverage and are published as the Published Kinase 
Inhibitor Set (PKIS). Compound collections such as PKIS can help to 
mitigate the gap in kinome target coverage beyond TK [124, 125]. The 
compound collection was made available for research use with structure 
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and bioactivity data. The kinome activity of the compounds have been 
assayed (NANOSYN) against 220 kinases, which includes 89 TKs and 
131 non-TKs. Among non-TKs, it covers 34 AGC, 34 CAMK, 25 CMGC, 











Figure 4: Current kinome coverage of kinase inhibitors in clinical evaluation. The highest 
clinical status for the kinase inhibitor is considered. Illustration produced using KinMap 
from BioMed X (kinhub.org/kinmap/).
33 
3.2.2. Oncogenic target deconvolution 
 
Recent development in omics profiling has allowed extensive 
exploration of the genomic alterations in patient tumors, leading to a 
better understanding of the genes playing a role in cancer [126-128]. 
Profiling of mutational and histological variations in tumors from 
various cancer types have revealed that the genomic landscape of 
tumors is very heterogeneous and complex, making it difficult to pin-
point the driver genes [129]. Moreover, it has been difficult to translate 
this knowledge into clinical practice as the functional consequences of 
many genetic alterations are not known, and often the altered gene 
products are difficult to target with pharmacologically agents [130]. This 
calls for alternative ways to identify the signaling addictions of cancer 
cells.  
 
Phenotypic high-throughput chemical screenings provide 
complementary (omics) information about the drug sensitivity 
phenotypes of cancer cells, and have made it possible to identify 
promising drugs for anticancer treatment. By integrating the 
information of drug response of cancer cells with their known 
mechanism of actions or primary targets, it is possible to identify the 
driver addictions or biological processes or pathways that are important 
for the survival of cancer cells [131, 132]. However, most drugs are 
promiscuous and exhibit polypharmacology effect [133, 134], therefore 
making it difficult to attribute the effect of the drug to the direct 
inhibition of its primary on-targets. Several approaches have been taken 
previously to integrate the off-target effects of drug with drug response 
profiles to identify cell-line specific driver addictions. For example, 
Tang et al utilized a systems pharmacology approach to predict the cell 
line specific dependencies by mapping the drug target inhibition 
network with drug screen data [135]. In other study, Al-Ali et al used a 
machine learning approach to de-convolve cell line specific kinase 
targets utilizing the kinase selectivity profiles and drug response profiles 
[136]. Similarly, other molecular profiles can also be integrated with 
drug response profiles and drug target binding profiles to identify novel 
target addictions. For instance, Rees et al correlated the drug sensitivity 
profile in a panel of cell lines with their gene expression levels to 
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identify novel mechanism of action of drugs as well as novel target 
addictions [137].  
 
3.3. Cell health measurement system 
 
Most commonly, cell proliferation, cell viability and cytotoxicity assays 
have been used to test the effect of certain compounds on the cells [138]. 
Cell proliferation/ cell growth assays are the assays to measure the 
change in proportion of dividing cells in a given condition. Two major 
ways to quantify cell proliferation are measurement of DNA synthesis 
and amount of cell proliferation markers (antigens). Cell viability 
assays, also regarded as indirect cell proliferation assays, assess the 
number of viable cells by quantifying metabolic activity or amount of 
ATP. Highly sensitive and robust assays compatible with a multi-well 
plate reader formats are preferred in high throughput screening (HTS) 
approaches. As HTS mostly is performed as an end point assay, highly 
robust and reproducible detection methods are favored. The first HTS 
compatible homogenous cell viability assay developed was the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium 
(MTT) salt colorimetric assay [139]. The MTT assay measures the 
reducing capability of viable cells. The colorless MTT is reduced to a 
purple formazan dye by the mitochondrial NAD(P)H-dependent 
oxidoreductase enzyme [140] (Figure 5A).   
 
Later on, it was realized that the MTT assay was not robust enough for 
HTS because it required additional step to dissolve the water insoluble, 
precipitating formazan product before reading the absorbance. It was 
also found to be toxic to cells and interfere with different compounds, 
hence giving false hits [141-143]. Other refined tetrazolium reagents like 
MTS, XTT, WST were subsequently developed, which unlike MTT 
generate water soluble formazan dyes [144-146] and therefore are easier 
to use in HTS assays. The amount of generated reduced dye is 
proportional to number of viable cells. Similar to the concept of 
tetrazolium reagents, cell permeable, fluorescence based redox indicator 
‘resazurin reduction assay’ was developed later [147]. It was highly 
appreciated in the HTS application as it is more robust and sensitive 
assay [148]. It measures the redox capability of viable cells 
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(mitochondrial activity) to transform resazurin (Alamar blue) to 
fluorescent resorufin (Figure 5B).  
 
Technological advancements in establishing stable versions of firefly 
derived luciferase led to the development of robust cell viability 
measurement assays detecting the amount of cellular-derived ATP (a 
well validated cell viability marker), which were rapidly adapted to HTS 
[149] (Figure 5C). For example, the CellTiter-Glo (Promega) reagent 
works in a “add-mix-measure” format, eliminating all the multiple steps 
like media removal, cell washing and reagent dilution. The reagent lyses 
the cells and the ATP is distributed homogenously in the reaction 
mixture making it a robust measurement system. It was widely accepted 
in HTS settings since it was significantly more sensitive than previous 
assays (higher signal window as well allowing detection of as few as 10 
cells/well) and had faster detection time compared to previous 
fluorescence or absorbance systems.  
 
Further development of engineered luciferases (NanoLuc, derived from 
a marine shrimp luciferase) and a small molecule pro-substrate has 
allowed ‘real-time’ monitoring of cell health or quantifying viable cell 
number with a sensitive luminescence readout [150]. The pro-substrate 
is cell permeable, hence viable/ metabolically active cells reduce the 
pro-substrate to substrate, which diffuses back to culture medium 
where it reacts with the luciferase producing a luminescent signal 
(Figure 5D).  NanoLuc is small (19 kDa) relative to firefly luciferase (60 
kDa) or Renilla luciferase (36 kDa) and also have broader thermal and 
pH stability [151]. NanoLuc produces a signal that is 150-fold brighter 
than firefly and Renilla luciferases, has fastest response, and has 
exceptional stability in vitro, making it an ideal detection system in high 
throughput settings [151]. The real-time measurement provides 
advantages such as monitoring cell proliferation over time, which 
cannot easily be incurred from endpoint viability readouts and allows 
the user to follow compound effects over time.  
 
As the basic principle of viability assays is to estimate the number of 
viable cells left after treatment, their readouts lack the crucial 
information about the extent of dead cells. Dye exclusion assays, which 
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utilize cell membrane non-permeable dyes to stain dead cells, have also 
been adopted in drug screening approaches [152] (Figure 5E). The most 
commonly used dyes are propidium iodide, ethidium bromide and 
cyanine dyes which bind to DNA of the membrane compromised cells. 
Cyanine dyes are more preferred for real-time cytotoxicity measurement 
in HTS settings as they have better sensitivity and reduced toxicity 
[153]. Some examples of cyanine-based dyes are CellTox Green 
(Promega) and SyTox Green (ThermoFisher). Cyanine dyes have two or 
more positive charges making them totally cell impermeable as 
compared to ethidium bromide which has single positive charge 
resulting in slow entry of dye even in viable cells [154]. Unlike 
propidium iodide, the cyanine dyes are non-toxic to the cells, allowing it 
to be used as an end point as well as kinetic measurement of 
cytotoxicity. With a multiplexed cyanine dye and RealTime-Glo assay, 





Figure 5: Illustration of different cell viability and cytotoxicity assays. A) MTT assay. B) 
Resazurin reduction assay. C) CellTiter-Glo assay.  D) RealTime-Glo assay. E) Dye 
exclusion toxicity assays. 
  
Other types of assays that have been used are apoptotic assays, which 
detect different stages of programmed cell death (like DNA 
fragmentation, caspase activity, loss of membrane polarization). Some 
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new apoptotic assays like dynamic BH3 profiling give more mechanistic 
insight into cell death [155]. However, all apoptotic assays share a 
common drawback that elevated level of apoptotic signaling does not 
necessarily result in cell death [156, 157]. This holds especially true for 
cancer cells, which can survive high levels of caspase activity or severe 
aneuploidy [158]. Besides, the temporary nature of apoptosis makes it 
challenging to capture the apoptotic signal at the right time and once 
the cells are dead, the apoptotic signal is typically lost. Therefore, 
apoptotic assays should preferably be complemented with cytotoxicity 
readouts. Even when the apoptotic and cytotoxicity responses correlate 
with each other, the dynamics of apoptosis varies a lot between the 
drugs and cell lines. This complicates the comparative analysis between 
the models and treatments.  
 
The technical advances in microscopy and flow cytometry techniques 
has allowed the complementing of the multi-well plate reader assays 
with high content analysis. These systems provide much added 
information on cellular feature/phenotypes, like assessing multiple 
cellular markers and differentiating distinct phenotypic subpopulation 
[159-161]. These additional data points become especially relevant when 
addressing drug sensitivities in highly heterogenic primary samples. 
The major drawbacks with these technologies however are that they are 
quite laborious, technically challenging and expensive, therefore often 
limiting their use in dedicated facilities. In addition, data analysis and 
integration for these techniques remain a challenge.  
 
Reduction in cell viability is often assumed to be correlated with 
enhanced cytotoxicity, which is not always the case. Moreover, simple 
viability or cytotoxicity assays do not always provide sufficient data to 
address mechanistic complexity in inhibition of many targets. 
Therefore, it is important to understand what cellular event we want to 
monitor in response to certain compounds and then choose the 
detection assay and interpret the data correctly.  
 
3.4. Drug response quantification  
 
Different parameters of dose-response curves are used to quantitate the 
effect of compounds in high throughput drug screening studies. The 
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most commonly used parameters are half maximum effects such as the 
half maximal effect concentrations (EC50, IC50), or summary metrics, 
such as area under the dose-response curve (AUC), activity area (AA) or 
multi-parametric drug sensitivity score (DSS) (illustrated in Figure 6) 
[83, 94, 96, 106, 162-164]. The whole concept emerged from the seminal 
NCI-60 tumor cell line screening effort where drug sensitivity and 
resistance was quantified by different parameters, which also 
incorporated initial cell density at initiation time T0 and therefore 
allowed for estimation of the concentration at which 50% growth 
inhibition occurs (GI50, concentration at which increase in cell density in 
treated condition is half of control condition), total growth inhibition 
(TGI, concentration at which cell density at treated condition is equal to 
initial seeded cell density) and 50% lethal concentration (LC50, 
concentration at which cell density in treated condition reaches half the 




Figure 6: Illustration of different parameters of dose response curves applied for 
quantification of drug effects. IC50: half maximal inhibitory concentration, EC50: half 
maximal effective concentration, DSS: drug sensitivity score, AUC: area under the dose-
response curve, AA: activity area. 
 
Traditionally, in high throughput drug screening approaches, the end 
point drug effects are recorded and presented as percent inhibition (PI), 
calculated by normalizing the estimated viable cell counts with negative 
(vehicle, no effect) and positive (known killing agent) controls [83, 94, 
99]. However, such kind of end point assays disregard the dynamic 
variability that could occur due to experimental artifacts such as cell 
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seeding discrepancy, differing growth rate of the cells, changes in 
background noise over time or signal bleed-through, among others 
(Figure 7). This highlights that noise-prone data are being collected and 
could partly explain the ongoing debate on inconsistencies observed in 




Figure 7: Schematic diagram illustrating different time dependent experimental artifacts 
encountered in the end point high throughput drug screening assays. A) Figure representing 
different background noises, signal bleed through and false hit from auto-fluorescence drug. The 
signal bleed through is illustrated in the figure as follow: ‘Blank’ well is not supposed to give any 
luminescence signal but due to highly luminescent neighboring wells blank well also exhibits some 
luminescence. Most studies ignore positive control or background noise [82, 169, 170], which can 
grow over time and skew the drug effect analysis. B) Representation of differential luminescence 
signals at an end point because of cell seeding discrepancies. A skewness of single point in dose 
response curve due to non-uniform cell seeding can lead to a false over/under estimation of drug 
effect. C) Effect of growth rate of cells results in over/under estimation of drug response 
quantification. Figure describes an example where the effect of cytostatic drug X (completely blocks 
the cell division) in three different cell lines with differing growth rate. Initially equal number of 
cells are seeded for all three A, B, C cell lines, the drug exhibit same effect in all the cell lines 
limiting the cell number to the initial count. But when normalized/compared to negative control 
where the final cell densities are different corresponding their growth rates, the effect of drug X 
appears different, making it seem less effective against cell line A, moderately effective against cell 
line B and highly effective against cell line C.  
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Along with the seminal NCI60 metrics (GI50, LC50), two independent 
drug response metrics GI50 and TGI were recently devised to limit the 
time-dependent biases produced by the end-point measurement 
metrics, namely the growth rate (GR) metric and drug induced 
proliferation (DIP) rate [169, 170]. Both of these metrics take into 
account cell-line specific growth rates as well as drug-induced growth 
rates, and experimental artifacts including cell seeding discrepancy. 
However, both of them as well as the seminal NCI60 metrics ignore the 
positive control and/or background noise. Both GR and DIP are based 
on real-time imaging data. Hence, even though they seem like very 
promising metrics, GR and DIP cannot be readily be implemented in 
high throughput drug screening.  
 
 
Technological advancement in the high content live imaging methods 
would resolve most of these artifacts and help in better understanding 
drug effects. However, the lack of such techniques compatible with HTS 
still normally limits drug effect assessment to endpoint measurements. 
Recent developments of live viability measurement assays has provided 







Aims of the study 
 
The main aim of the thesis was to explore drug vulnerabilities based on 
functional profiling of triple negative breast cancer (TNBC) cell lines to 
better define the molecular background of TNBC and to identify novel 
druggable targets. The aims can be briefly summarized as follows: 
 
1. Functionally classify TNBC cell lines, directly connecting them to 
druggable vulnerabilities  
2. Kinome-wide exploration of TNBC cell lines to identify and 
establish novel and putative drug targets. 




Materials and methods 
 
Material and methods used in this thesis are described in detail in the 
original publications (I-III). Below is the summary of materials and 
methods in brief.  
 
4. Cell lines 
 
Twenty-three different breast cancer cell lines along with one non-
cancerous breast epithelial cell line and one pancreatic cancer cell line 
were used for this thesis work. The use of different cell lines in 
respective studies are highlighted in Table 2. The cell lines were 
obtained from ATCC or DSMZ except MIA-PaCa-2, which was a 
generous gift from Prof. Channing Der, University of North Carolina, 
NC, USA. All the cells were maintained in their respective media (Table 
2) at 37°C with 5% CO2 in humidified incubator as per provider’s 
instruction. DMEM with 2.2 g/l sodium bicarbonate (adapted for 5% 
CO2 incubation), RPMI-1640 and McCoy media were purchased from 
Life Technologies, Lonza and Sigma-Aldrich respectively. 
 
5. Inhibitors  
 
A compound collection consisting of 351 different oncology compounds 
covering wide range of molecular targets were used in the study 
(Appendix 1). The collection consisted of commercially available 
approved (43%), investigational (45%) and pre-clinical experimental 
(12%) anti-cancer compounds. The compounds were obtained from the 
National Cancer Institute Drug Testing Program and the Structural 
Genomics Consortium or purchased from Active Biochem, Axon 
Medchem, Cayman Chemical Company, ChemieTek, Enzo Life Science, 
LC Laboratories, MedChemExpress, Merck, Santa Cruz Biotechnology, 
Selleck, Sequoia Research Products, Sigma-Aldrich and Tocris 
Biosciences. The compounds were dissolved in DMSO or water and 
stored in pressurized Storage Pods (Roylan Developments Ltd.) filled 
with inert nitrogen gas according to the manufacturer’s instructions.  
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Table 2: The list of cell lines used in the studies. 
 









RPMI 1640+ 5% FBS+ 2 mM 
glutamine 





DMEM + 10% FBS+ 2 mM 
Glutamine+ 1 mM sodium pyruvate 

















DMEM+ 20% FBS+ 2 mM glutamine+ 
0.01 μg/ml EGF  








ATCC DMEM + 10% FBS 1500 II 
HCC-1143 breast carcinoma DSMZ 
RPMI 1640+20% FBS+ 2 mM 
glutamine 
1000 I, III 
HCC-1599 breast carcinoma DSMZ RPMI 1640+ 10% FBS 8000 I, III 
HCC-1937 breast carcinoma ATCC 
RPMI 1640+10% FBS+ 2 mM 
glutamine 
1000 I, III 
HDQ-P1 breast carcinoma DSMZ DMEM + 10% FBS 1000 I, II, III  
BT-549 breast carcinoma ATCC 
RPMI 1640+ 10% FBS+ 2 mM 
glutamine 
1000 I, III 
CAL-51 breast carcinoma DSMZ DMEM + 20% FBS 2000 I, III 
Hs-578T breast carcinoma ATCC 
RPMI 1640+ 10% FBS+ 2 mM 
glutamine 
1000 I, III 
DU-4475 breast carcinoma DSMZ RPMI 1640+ 20% FBS 1500 I, III 
MFM-223 breast carcinoma DSMZ EMEM + 10% FBS + 2 mM glutamine 2000 I, III 
MDA-MB-453 breast carcinoma DSMZ DMEM/F12 + 10% FBS  2000 I, III 















ATCC EMEM + 10%FBS + 10 μg/ml insulin  1500 II, III 
MCF-10A noncancerous ATCC 
MEMB/F12+ supplement vials + 100 
ng/ml Cholera toxin 
1000 I, III 





6. Drug Sensitivity and Resistance Testing (DSRT) 
 
The drug sensitivity and resistance testing (DSRT) platform that has 
been described previously [94] was adopted for breast cancer cell lines. 
The compounds were plated to white clear bottom 384-well plates 
(Corning #3712) using an Echo 550 Liquid Handler (Labcyte) in 5 
increasing concentrations in 10-fold dilutions covering a 10,000-fold 
concentration range of (e.g. 1-10 000 nM). 100 μM benzethonium 
chloride (BzCl2) and 0.1% dimethyl sulfoxide (DMSO) were used as 
positive and negative controls respectively. All subsequent liquid 
handling was performed using a MultiDrop dispenser (Thermo 
Scientific). The pre-dispensed chemicals were dissolved in 5 μl of 
culture media, containing cytotoxicity measurement reagent (CellTox 
Green, Promega) and in study II viability measuring reagent (RealTime-
Glo, Promega) was additionally supplemented. Two viability reagents 
CellTiter-Glo (Promega) and CellTiter-Blue (Promega) along with 
cytotoxicity measurement dye CellTox-Green were explored in study I. 
Multiplexed RealTime-Glo and CellTox Green was explored in study II 
and CellTiter-Blue was used in study III. Twenty microliters cell 
suspension containing required number of cells (defined in Table 2) per 
well were seeded in the drugged plates. After 72 h incubation, the cell 
viability (luminescence for CellTiter-Glo and RealTime-Glo and 
fluorescence in case of CellTiter-Blue) and cytotoxicity (fluorescence) 
was recorded using a PHERAstar FS plate reader (BMG Labtech). 
 
7. DSRT Data Analysis 
 
The raw luminescence/fluorescence data were analyzed in Breeze 
software, an in house developed data analysis and management 
software to generate the dose response curves. Utilizing multiple 
parameters from the dose response curve, drug sensitivity score (DSS) 
was calculated for each single drug treatment [162].  For drug 
combinations, synergy score was calculated using Bliss independence 
model and ZIP model [171, 172]. The drug combination matrices were 




8. siRNA Screening 
 
The siRNAs were purchased from Qiagen or Ambion. Kinase siRNAs 
along with scrambled non-targeting siRNAs and death control siRNAs 
(8-10 nM final concentration depending on the experiment) were added 
to 384 well plates (Corning #3712) with the Echo 550 Liquid Handler 
(Labcyte). 5 μl of Opti-MEM (Life Technologies) containing 50 nl of 
Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) was 
added to each well of pre-siRNA-added plates using a MultiDrop Combi 
nl dispenser (Thermo Scientific) and incubated at room temperature for 
20 min on an orbital shaker. 20 μl of cell suspension (25000 cell per 1 
ml) were seeded on the siRNA plate and the plates were maintained in 
culture for 96 h. In case of pooled screening, three different siRNAs 
against a particular target were mixed at equal concentration to obtain a 
final combined concentration of 10 nM. The viability of cells after siRNA 
treatments was assessed with CellTiter-Glo (Promega). The 
luminescence measurements were converted to % inhibition in respect 
to positive and negative controls.  
 
9. Statistical analyses 
  
Statistical analyses were performed using GraphPad Prism software or 
R programming. Pearson correlation coefficient was used to evaluate 
the correlation between screening data (DSS). Root mean squared 
distance (RMSD) and baseline distance were used to evaluate the 
improvement in dose response curve fits. Wilcoxon rank sum test was 
used to assess the difference in mean RMSD, and F-test was used to 







Results and discussion 
 
10. Identification of TNBC selective drug sensitivities 
 
10.1. Viability inhibition does not directly correlate with 
cytotoxicity  
 
Typically, multi-well plate compatible cell viability measurement assays 
are preferred in high throughput chemo-sensitivity screenings. The 
metabolic activity of the cells is measured as an estimate for number of 
viable cells. Some commonly used methods involve quantifying the 
amount of energy molecules like ATP, NADH/NADPH or the redox 
capability of the cells (as described in Figure 5)[138, 174]. Generally, a 
reduction in viability is assumed to be directly correlated to cytotoxicity. 
Therefore, to test whether viability inhibition complements cytotoxicity, 
along with cell viability measurement assays (CellTiter-Glo, measures 
amount of ATP; CellTiter-Blue, measures redox potential of cells), we 
also applied a cytotoxicity measurement assay (CellTox Green, a 
membrane impermeable DNA binding dye) in study I. We collected a 
panel of breast cancer cell lines including 16 TNBC, 2 HER+ and one 
non-cancerous triple negative breast epithelial cell line (details in table 
1) that we screened against 301 oncology compounds (listed in 
Appendix 1). The drug effect was recorded as drug sensitivity score 
(DSS) [162]. Average DSS for all compounds screened across 19 cell 
lines were computed, both for viability and cytotoxicity data.  
 
Upon comparing average DSS of tested compounds, the two 
independent cell viability assays (CellTiter-Glo and CellTiter-Blue) 
yielded high correlation (rcor= 0.89, Figure 8A). On the other hand, a 
comparison of the multiplexed cell viability (CellTiter-Glo) and 
cytotoxicity (CellTox Green) readouts revealed lower correlation (rcor= 
0.67, Figure 8B). Most single agent anti-cancer compounds showing 
activity for the viability readout had no or little cytotoxic effects, rather 
only caused a cytostatic effect. A relatively low number of drugs 
exhibited cytotoxic effect (0nly 20 drugs had average DSS more than 5). 
The classes of compounds that displayed high viability inhibition but 
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failed to kill the cells included PI3K/mTOR inhibitors (such as 
dactolisib, GSK2126458, PF-04691502), CDK inhibitors (alvocidib, 
SNS-032, UCN-01), HSP90 inhibitors (tanespimycin, BIIB021), 
NAMPT inhibitor (daporinad), tubulin stabilizer (taxanes), protein 
synthesis inhibitor (omacetaxine), and RNA and DNA synthesis 
inhibitor (dactinomycin). The compounds showing such effects are 






































































Figure 8: Difference between the cytotoxic and cytostatic effect. Upper panel shows 
scatter plots comparing DSS computed using two different viability readouts (A) and 
viability and cytotoxicity readouts (B). The drugs exhibiting strong viability inhibition but 
comparatively less toxicity are highlighted in green. Case examples of such drugs exhibiting 
high viability inhibition and low toxicity; (C) mTOR/PI3K inhibitor dactolisib; (D) CDK 
inhibitor SNS-032. Error bar represents SEM (n=3); “W” represents a condition where 
drug is washed away after 72 h.  
 
There could be two reasons behind drug responses displaying high 
viability inhibition but no corresponding toxicity. The drug effect might 
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either be a reversible static effect or transient metabolic shutdown or a 
non-reversible/permanent metabolic shutdown such as senescence. 
Therefore, to unravel the nature of such drug classes we collected 8 
drugs from the different drug classes that exhibited no apparent toxic 
effect but dramatic viability inhibition in most of the cell lines, including 
the mTOR/PI3K inhibitor dactolisib, the PI3K inhibitor pictilisib, the 
CDK inhibitor SNS-032, the NAMPT inhibitor daporinad, the IMPDH 
inhibitor AVN-944, and the survivin inhibitor YM155. A drug effect 
reversibility test was performed with these drugs against a 
representative TNBC cell line (CAL-51) to explore their mechanism of 
action, where after the drug (used at 10 times its IC50) treatment for 72 
h, either was replenished or washed away and the cells were maintained 
in culture for 6 more days while their growth was followed in a live cell 
microscope. The cell growth (confluence) was monitored/recorded for 
the whole period of time. Detailed experimental results can be found in 
Study I, Figure 3. 
 
Strikingly, we found that the cytostatic effects of all the drugs were 
reversible and in some instances the cells overcame the inhibitory effect 
even in the presence of the drug after a few days. The reversible effects 
were well-pronounced for dactolisib, pictilisib, daporinad and AVN-944. 
In the presence of drugs the cell growth was ceased/inhibited but as 
soon as the drugs were washed away the cells started dividing again 
(dactolisib behavior shown in Figure 8C as a representative effect). 
Furthermore, everolimus, methotrexate, SNS-032, and YM155 only 
caused a transient growth inhibitory effect and in a matter of few days 
their effect was lost; the cells began to grow normally even in the 
presence of the compounds (SNS-032 behavior shown in Figure 8D as 
representative effect). The resistance developed by the cells against 
these compounds is most likely because of cellular reprogramming 
triggered in response to the drugs. This implies that these agents alone 
might not be efficacious in the clinic, rather they should be combined 






























Figure 9: Assessing cytotoxicity is important to unravel synergistic and antagonistic 
effects in drug combination screening. A) In DU4475, a combination of ponatinib and 
trametinib exhibits synergistic effect that is more pronounced in cytotoxicity readout. B) In 
DU4475, a combination of dactolisib and trametinib displays an antagonistic effect, which 
is only pronounced in the cytotoxicity readout. 
 
We found that assessing cytotoxicity along with viability drug 
combination studies provide much more information than mere 
viability readouts, for example in testing concentration combination 
matrices. The real synergistic (lethal) effect might be obscured in the 
viability readout for those kinds of drugs posing high viability inhibition 
but no toxicity, as single drug already showed the maximum viability 
inhibition effect masking the actual combination effect. Such examples 
are illustrated in Figure 9A, where synergy between trametinib (MEK 
inhibitor) and ponatinib (pan-selective TK inhibitor) in DU4475 cells 
was found to be more pronounced in cytotoxicity readout. Additionally, 
toxicity readout also captured counterproductive antagonistic effects, 
which were missed by viability measurements. For example, Figure 9B 
illustrates the antagonism between trametinib and dactolisib in 
DU4475, which was only observed with cytotoxicity readout. Here, 
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trametinib almost completely inhibited the metabolic activity of 
DU4475 above 1 nM already as a single agent obscuring the effect of 
added dactolisib, whereas the magnitude of cytotoxicity does not 
correspond to the metabolic inhibition, allowing exhibition of 
antagonistic effect. 
 
These results highlighted the common misconception that reduced 
viability directly correlates to the induction of cytotoxicity. Strong 
viability/metabolic inhibition does not necessarily represent cellular 
toxicity, rather it may just represent metabolic shutdown/cell-cycle 
arrest or quiescent phenotype of the cells. Cells can ultimately reverse 
these kinds of effects. This highlights that drugs/compounds with 
reversible cytostatic responses may not be the ideal therapeutic in 
clinical setting. Hence, we need to thoroughly comprehend drug 
mechanisms beyond mere viability inhibition. 
 
10.2. Drug sensitivity based functional profiling of TNBC  
 
With an aim to functionally classify TNBC, a panel of TNBC cell lines 
representing all 6 transcriptomic subtypes [47] (Figure 10A) were 
clustered based on the selective drug sensitivities of 301 oncology 
compounds, which included a broad array of drugs including 
conventional cytotoxic chemotherapies, metabolic modifiers, apoptotic 
modulators, kinase inhibitors, hormonal therapies, immune-
modulators, epigenetic modifiers, and others (Appendix 1). To 
determine the selective drug sensitivities towards TNBC (or a particular 
cell line), selective DSS (sDSS) was calculated for each compound by 
subtracting the average DSS of that compound over a large panel of in-
house cell line screening data (150 diverse cell lines comprising of 5 
different tissue types, based on CellTiter-Glo assay) from the cell line-













































Figure 10: Variability between drug sensitivity and transcriptomics based TNBC 
subtyping. A) The tested cell lines grouped and colored based on transcriptomics based 
TNBC subtypes [47]. B) A clustered heat map based on sDSS of TNBC compared to the 
average response of a panel of 150 different cell lines from 7 different tissue types (viability 
readout). This only represents a portion of heat map where drugs are clustered vertically 
and cell lines horizontally (cell lines are color coded according to their transcriptomic 
subtypes as highlighted in A). Red (positive sDSS)) represent selective responses whereas 
blue (negative sDSS) represents below average responses. C) Cell line clustering based on 
selective drug sensitivity (sDSS) based on cytotoxicity data (sDSS calculated by subtracting 
average DSS of 30 cell lines originating from 3 tissue types). 
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While comparing sDSS across the TNBC cell lines, we found that the cell 
lines exhibited highly heterogeneous response patterns towards the 
compound library and not a single compound showed selective 
responses in all the TNBC cell lines tested. We further tried to 
cluster/subgroup the TNBC cell lines based on their drug vulnerabilities 
and match the clustering with published transcriptomics based TNBC 
subtypes [47]. Strikingly, drug sensitivity driven clustering was not 
directly linked to the transcriptomic subtyping of the cell lines (Figure 
10B). In addition, we also performed the cell line clustering based on 
individual compound or classes of compounds sensitivities, but as 
opposed to previously reported studies [47-49], we could not link 
specific vulnerabilities to any specific transcriptomic-subtype. 
 
Further, clustering analysis on cytotoxicity measurement based drug 
sensitivity data (sDSS calculated as difference against an average DSS 
over 30 cell lines screened in house) yielded a different pattern than 
those of both viability-based and transcriptomics-based subgroupings. 
In spite of heterogeneity in drug responses, cell lines could be broadly 
divided into two groups, sensitive and insensitive based on cytotoxicity 
data. The cell lines in the sensitive group included MDA-MB-231, MDA-
MB-468, CAL-51, CAL-85-1 and Hs-578-T as they showed sensitivity 
(cytotoxicity) towards mitotic inhibitors (including taxanes, CDK 
inhibitors, Vinca alkaloids, topoisomerase I inhibitors) and HDAC 
inhibitors (Figure 10C) along with a few other inhibitors.  
 
We further looked for molecular markers that could be linked with 
cytotoxic effect of the sensitive cell lines to respective drugs/classes. 
First, we explored recurrent genetic alterations prevalent in TNBC. 
Mutations in DNA repair genes (BRCA2 and ATM) appeared to possibly 
be enriched in sensitive cell lines but no striking link between mutations 





Figure 11: Association analysis between the recurrent genetic alterations in TNBC with 
the observed cytotoxic effects of different classes of drugs.  
 
Next, we analyzed published protein marker expression profiles (reverse 
phase protein array data, Daemen et al. 2013) of the tested cell lines 
[85]. By comparing proteomic profiles of mitotic inhibitors (taxanes, 
CDK- and CHK- inhibitors) sensitive and insensitive cell lines, we 
identified differential levels of protein markers linked to the cytotoxic 
responses to mitotic inhibitors. For example, higher protein levels of 
PKCα, FGFR1, c-Jun, Caveolin-1 and low levels of RAB25, pSTAT3 
(Y705), NOTCH3, Bcl-2 and HER2 were observed in antimitotics-
sensitive cell lines than in insensitive cell lines (Figure 12). Supporting 
our discoveries, all these proteins (and their respective levels) has been 
linked to TNBC drug responses in other studies. For example, high 
levels of pSTAT3, Bcl-2 and HER2 have been reported to correlate with 
resistance to chemotherapy [175-177]; high level of c-Jun, RAB25 and 
low level of caveolin-1 have been linked to poor prognosis [178-180]; 
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low levels of NOTCH3 has been linked to apoptosis induction [181]; and 
high levels of PKCα and FGFR1 have been linked to growth of TNBC cell 
lines [182, 183].  
 
Similarly, differential levels of protein markers were found between 
proteasome inhibitor-sensitive and -insensitive cell lines. Proteasome 
inhibitor-sensitive cell lines exhibited elevated protein expression levels 
of PAI1, MKP-1 and pAKT (T308), phospho-p38 (T180/182) and low 
levels of PTEN, NOTCH3 and CCND1. Our results suggest that patient 
stratification based on these protein markers could be explored in 
clinics for the treatment of TNBC patients with mitotic inhibitors (such 




























Figure 12: Potential predictive biomarkers for lethal effect of antimitotics. A) DSS based 
heat map illustrating discrete effects of different mitotic inhibitors, broadly dividing cell 
lines to sensitive and insensitive groups. B) Differential expression of different protein 
markers between mitotic inhibitor sensitive and insensitive cell lines. (Protein expression 














































































































































































All in all, the results advocate that precision/personalized therapeutic 
strategies-based proteomic biomarker stratification may be a more 
effective way to target TNBCs rather than therapies based on 
transcriptomics subtyping, or that a more refined analysis of TNBC 
transcriptomics is needed for linking it to broad drug sensitivities.  
 
10.3. mTOR inhibitors antagonize the effect of diverse classes 
of drugs 
 
mTOR is an extensively studied kinase and regarded as a potential 
cancer therapeutic target [184]. Recently, the rapamycin analogue 
everolimus was approved for HR+, HER2- breast cancer and numerous 
other mTOR inhibitors are being currently evaluated in clinical settings.  
However, we found that at the cellular level PI3K/AKT/mTOR pathway 
inhibitors were non-cytotoxic to almost all cell lines screened except 
CAL148. To achieve further insight, we performed combination testing 
with mTOR inhibitors with our oncology drug collection (301 
compounds) with an aim to identify compounds that enhance the 
cytotoxic effect of mTOR inhibitor. We profiled the drug responses of 
the mTOR sensitive cell line CAL-51 (viability data) in the absence and 
presence of single concentrations (ten times IC50) of mTOR inhibitors: 
the rapalog everolimus (10 nM) (Figure 13A) and the ATP competitive 
mTOR kinase inhibitor dactolisib (100 nM) (Figure 13B).   
 
Surprisingly, we found that the mTOR inhibitors had an almost 
exclusive antagonistic effect on the cell viability and cytotoxic activity of 
other anti-cancer drugs, which includes anti-metabolites, anti-mitotics, 
topoisomerase, HDAC, PARP, and proteasome inhibitors along with few 
kinase inhibitors, among others (a detailed list can be found in Study I, 
Figure 6 and supplementary Figure 4). One plausible reason for this is 
that mTOR inhibition shuts down the cell metabolism and growth 
thereby limiting/blocking the effect of other anti-cancer drugs. 
Daporinad, a NAMPT inhibitor, exhibited synergism in combination 
with everolimus but only as a cytostatic response (Figure 13A). Our 
results suggest that a cautious consideration should be taken while 
combining mTOR inhibitors with conventional chemotherapies 
including standard first line of therapies like gemcitabine and 
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doxorubicin, which might be counterproductive in the clinical setting. 
Even though our results are limited to in vitro level and might not fully 
imitate the responses in a complex in vivo setting, it urges for caution in 




Figure 13: mTOR inhibitors exhibit antagonistic effect when combined to various classes 
of drugs in CAL-51. Scatter plot comparing DSS for mono-treatment (x-axis) with DSS for 
combination effect (y-axis) of 10 nM everolimus (A) and 100 nM dactolisib (B). The drugs 
with DSS difference higher than 10 are highlighted in the plots, different colors represent 
respective drug classes as listed in the color legend. 
 
11. Normalized Drug Response (NDR) 
 
11.1. Formulation of NDR metric  
 
Typically, in vitro and ex vivo drug screening experiments are typically 
carried out as an end point assay (most often 72 h), where the effects of 
the drugs are assessed utilizing different viability or cytotoxicity 
measurement systems, covering a given concentration range of the 
drug. A normalized drug response is often generated as % inhibition 
(PI) values, which are calculated by normalizing the estimated viable 
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cell counts with negative (non-effective agent, vehicle) and positive 
(total killing agent) controls. Alternatively, growth inhibition (GI) values 
are used in some studies [82, 102], which considers growth rate of cell 
line (calculated as cell count at 72 h minus cell count at 0 h in non-
treated cells). In these cases, the 72 h and 0 h data are extracted from 
two different replicate plates. 
 
The end point PI-based drug effect quantification disregards the 
dynamic variability that occurs due to experimental limitation/artifacts, 
including uneven cell seeding, variable growth rates of cells, and 
background noise. This leads to the problem related to data 
reproducibility or consistency. To address such limitations, we devised a 
novel response metric, normalized drug response (NDR) that accounts 
for all time-dependent assay artifacts including signal escalation rate in 
positive and negative control as well as in drug-treated conditions. NDR 
is calculated utilizing two-point screening readouts, first at the start of 
the experiment and second at the end-point. This was possible due to 
recently developed real-time measurement systems [150].  
  




where the fold change between the readouts at start and end-point of -




In other words, NDR was computed by two-step normalizations, where 
each data point was first normalized to its initial readings and then to 
the positive and negative controls.  
 
NDR not only scored the drug effect in single value but also defined the 
drug effects/behaviors (Figure 14). Grounded on the single NDR values, 
























Figure 14: Illustration of NDR formulation. A) Simulation of NDR calculation at a specific 
time point (here 80 h of treatment) considering the dynamic change of different treatment 
conditions (blue line represents drug treatment, green represents negative control and red 
represents positive control. B) Illustration of range of drug effects respective to NDR based 
drug response quantification. 
 
11.2. NDR improved reproducibility and drug response curve 
fits  
 
The consistency in large-scale drug screening approaches are highly 
debated [163, 166-168]. Thus, we investigated if the NDR metric could 
improve the reproducibility in cell-based chemo-sensitivity screens. One 
of the major factors affecting the reproducibility is discrepant cell 
seeding. To explore this, we screened the breast cancer cell line MCF-7 
in duplicate experiments with 131 oncology drugs. MCF-7 grows as cell 
aggregates and is technically challenging to obtain as single cell 
suspension, and cell seeding uniformity is therefore often compromised. 
Based on a PI normalized readout, the two replicate experiments were 
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complete growth inhibition 
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highly discrepant, whereas NDR normalization markedly improved the 
consistency/reproducibility (Figure 15A). Z’-factor, which is one 
commonly used quality control measures for screening (should be ≥0.5)  





Figure 15: NDR improved reproducibility and quality of high throughput drug screening. 
A) Comparisons of replicate plates where the drug effects are assessed with PI and NDR. 
NDR cleaned up the noisy PI data. B) Bar diagram showing the improved Z’-factor of using 
NDR over PI.  
 
Thereafter, we evaluated whether NDR improved drug response curve 
fitting, which is critical in drug response quantification. For this, we 
evaluated two dose response quality measures, root mean squared 
distance (RMSD) and baseline distance from dose response curves 
(Figure 16A). Ideally, both measures are zero. We found that NDR 
significantly improved both RMSD and baseline distance values of dose 
response curves (Figure 16). Further, we used NDR method to analyze 
existing datasets and observed significant improvement in RMSD and 
baseline distance values for already existing drug screening datasets, 
including those from the Genomics of Drug Sensitivity in Cancer 
(GDSC1000) [89, 105] and Cancer Therapeutics Response Portal 
(CTRPv2) [106, 164] (Figure 16D,E) projects. Since the pre-existing 
datasets lacked the initial time point data, estimates based on cell-
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Figure 16: NDR significantly improves curve fitting. A) Schematic representation 
(definition) of RMSD and baseline distance (BD). B) Box plot comparing the average 
RMSD and baseline distance computed for dose response curves in MDA-MB-231 cell line 
between PI and NDR screened in house at FIMM. C) An example illustrating the improved 
curve fits of EGFR/HER2 inhibitor afatinib in MDA-MB-231 from FIMM dataset. D), E) 
RMSD and baseline distance comparisons in GDSC1000 and CTRPv2 respectively. 
**p<0.05, ***p<0.005.  
 
Because of the limited number of screening data points, even an error in 
an individual data point of the dose response curve can lead to 
over/under assessment of drug effects. Our results demonstrated that 
NDR not only reduced the experimental artifacts and improved curve 
fitting but also alleviated the experimental artifacts inherent to high 
throughput drug screening. The curve fitting improvements in pre-
existing GDSC and CCLE (CTRPv2) datasets emphasized the wide 
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applicability of NDR. Altogether, these results advocate that the 
application of NDR metric might partly solve the existing problems with 
inconsistency in large-scale drug screening studies. 
 
11.3. NDR reflected both viability and cytotoxicity 
 
Along with the real-time cell viability assay, we also utilized an 
independent cytotoxicity measurement system (CellTox Green) to cross-
validate the reliability of cell viability readout-based NDR drug 
response. Viability and cytotoxicity assays were multiplexed in the same 
experiment, screening five different cancer cell lines with varying 
growth rates, cellular phenotypes and tissue of origin. When comparing 
NDR-based dose responses of drugs to their cytotoxicity counterparts, 
good agreement was observed, while this was not the case with PI based 
data (Figure 17).  
 
First, in MDA-MB-361 and MIA-PACA-2 the magnitude of filanesib (a 
kinesin spindle protein inhibitor) effect based on NDR corresponds to 
the induced cytotoxicity (Figure 17A). In contrast, filanesib had no to 
little effect on other three cell lines, evident both in NDR-based and 
toxicity response curves. On the other hand, from the PI response 
metric, it was not possible to identify the response pattern seen with 
toxicity readout, and it did not allow us to distinguish the magnitude of 
the drug effect exhibited in the different cell lines.  
 
Second, unlike the PI metric, NDR can differentiate a cytostatic effect 
from a cytotoxic effect. For example, omacetaxine (a protein synthesis 
inhibitor) was toxic towards all cell lines tested except MCF-7, where it 
exhibited a cytostatic effect (Figure 17B). This behavior of omacetaxine 
towards MCF-7 was captured by the NDR but not the PI metric.  
 
Third, NDR eliminated the false hit calling, including over or under 
estimation of drug effect. For instance, based on PI, tipifarnib (a 
farnesyltransferase inhibitor) had a strong inhibition effect on MDA-
MB-231, which did not correspond to the cytotoxicity readout (Figure 
17C). NDR response, on the other hand, corresponded with the 
cytotoxicity and showed that tipifarnib had no inhibition effect in MDA-
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MB-231. The false positive effect seen with PI was due to uneven cell 
seeding; fewer cells had been dispensed in the wells with the highest 
two concentrations.  
 
Finally, NDR revealed growth-stimulatory effects of drugs that might be 
counterproductive in clinics. For example, in HDQ-P1 cells, 
pevonedistat (a NEDD8 activating enzyme inhibitor) exhibited growth-




Figure 17: NDR illustrates both cytostatic and cytotoxic behavior of drugs. Dose response 
curves of five cell lines based on %viability (PI), %toxicity and NDR-metric for four 
representative drugs. A) Differing magnitude of viability inhibition and cytotoxicity of 
filanesib on the cell lines. B) Cytostatic nature of omacetaxine on MCF-7. C) Non-effective 
behavior of tipifarnib on MDA-MB-231. D) Growth-stimulatory effect of pevonedistat on 
HDQ-P1. 
 
These results highlight that even with a single viability readout, a wide 
spectrum of drug behaviors can be evaluated employing the NDR-
metric. This is beneficial in high throughput drug screening approaches 
as it eliminates the time and cost for further cytotoxicity assessments.  
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12. Network pharmacology enables prediction of 
selective kinase combination addictions 
 
Kinases have gathered great attention as potential therapeutic targets 
against cancer due to their pivotal role in signal transduction and 
regulation of vast range of cellular activities including growth, survival, 
immune regulation and metabolism. In addition, they are often 
oncogenically mutated in cancers [109]. Even though kinases have been 
explored extensively, only a small number of kinase inhibitors have 
shown significant clinical efficacy so far. The availability of a large 
number of molecularly targeted compounds as well as drug 
vulnerabilities has created the opportunity to use their drug 
vulnerability data to predict the pathways/signaling nodes those are 
essential for cancer progression but are not necessarily mutated. 
However, most of the targeted compounds are promiscuous resulting in 
polypharmacology or ‘off target’ effects, which might play both ways as 
having counterproductive or enhancing therapeutic effects. To address 
the challenge of predicting key targetable vulnerabilities of cancer cells 
as well as efficacy of kinase inhibitors, we developed a phenotype-based 
systems pharmacology approach that integrates comprehensive drug 
sensitivity profiling with systems-level drug-target networks to provide 
functional insights into both single and multi-target models of the 
underlying oncogenic signaling cascades in individual breast cancer cell 
lines. 
 
To identify signal addictions, we used the observed drug responses (DSS 
values) of 21 breast cancer cell lines (19 from study I as well as the 2 
HR+ cell lines T-47-D and ZR-75-1) against 40 kinase inhibitors with 
extensive biochemical target profiling information (i.e. where kinome-
wide profiling had been performed using purified proteins in vitro). The 
drug target data was obtained from biochemical assay data (Kd values) 
against 205 kinases from the study of Davis et al [186], which were 
targeted by the screened 40 kinase inhibitors. A kinase was considered 
as a target of a particular inhibitor if the Kd value was below 1oo nM or 
at max 50-fold higher than the most potent Kd level of the given 
compound, whichever was lower. Analyzing cell line-specific inhibitor 
sensitivity profiles (DSS) together with drug-target network (kinase 
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targets of the respective inhibitor), we devised a kinase addiction 
quantification metric, which we termed kinase inhibitor sensitivity score 
(KISS). The analysis was based on the assumption that inhibitors of cell 
line specific essential kinases should effectively inhibit viability of that 
particular cell line. In other words, KISS for an individual kinase target 
is calculated as an average of drug responses over those drugs targeting 
the particular kinase (study III, Figure 1). For example, if an imaginary 
kinase X (KinX) is inhibited by three different drugs A, B and C with 
respective DSSs of 5, 10, 20 in a particular cell line, then the KISS for 
KinX in the given cell line is calculated as (5+10+20)/3=11.66.  
 
KISS was computed separately for each kinase target for each cell line. 
Our KISS approach successfully predicted known kinase addictions in 
respective breast cancer cell lines, including ERBB2 addiction in the 
HER2+ cell lines SK-BR-3 and BT-474; BRAF addiction in DU-4475, a 
cell line carrying a BRAF(V600E) mutation and PI3K in the PIK3CA 
mutant cell lines MCF-7 (carrying an E545K mutation) and T47D 
(H1047R mutation) (study III, Figure 2D). In addition, KISS predicted 
several novel cell line specific kinase addictions, which were further 
validated with independent siRNA and/or compound assessment. For 
example, ARK5, CAMK2a, MST1, SNARK1 in CAL51 and DYRK1A, 
DYRK1B, PKC  in Hs-578T (study III, Figure 4, Table S5). Strikingly, 
KISS-based clustering of TNBC cell lines displayed better agreement 
with transcriptomics based subtyping than the basic DSS-based 
subgrouping described in study I (study III, Figure 3). This could be 
because of the power of KISS to extract specific addictions that 
correspond to the subtype specific transcriptomic signatures, which are 
obscured in DSS data due to polypharmacology effect of drugs.  
 
Inhibiting a single node or pathway may not always be effective in 
treating cancer due to network rewiring and activation of compensatory 
signaling pathways leading to rapid development of drug resistance 
[187, 188] (also evident in study I). Hence, concurrent selective 
inhibition of multiple signaling pathways/nodes might provide a more 
effective way to treat cancers. However, identifying an effective drug 
combination a priori is quite challenging and it is currently impossible 
to experimentally test every possible drug combination and/or 
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treatment regime. Therefore, systems biology approaches that may 




Figure 18: Synergistic compound combinations and kinase pairs co-essentiality in 
HCC1937. A) Validation of the combinatorial KISS-predicted kinase co-inhibition using 
siRNA knockdowns. B) Drug combination matrices and their corresponding 3D synergy 
landscape visualizations illustrating synergy between the combined drug pairs, including 
axitinib (AURKC inhibitor) with dasatinib (EPHB6 inhibitor), pazopanib (TAOK3 
inhibitor) with bosutinib (GCK inhibitor), foretinib (CDK7 inhibitor) with bosutinib (GCK 
inhibitor) and nintedanib (PCTK1 inhibitor) with enzastaurin (GSK3b inhibitor). 
 
In-line with the concept, we further extended the KISS approach to 
predict kinase pairs whose co-inhibition leads to enhanced cellular 
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toxicity (synergy), which we called combinatorial KISS. Synthetic lethal 
kinase pairs were selected in way that the effect of co-inhibition is 
higher than the single kinase selective inhibitors. Combinatorial KISS 
aided in predicting synergistic drug combinations in an unbiased 
fashion. Combinatorial KISS successfully predicted co-inhibition of 
EPHB6 with AURKC, GCK with TAOK3, GCK with CDK7 and GSK3b 
with PCTK1 in HCC1937 cells. Combinatorial siRNA-mediated 
knockdown of these kinase pairs exhibited markedly enhanced viability 
inhibition as compared to the individual kinase inhibition (Figure 18). 
By mapping the kinases back to their respective inhibitors, these 
predictions ultimately provided synergistic drug combinations effective 
against HCC1937, including axitinib (AURKC inhibitor) with dasatinib 
(EPHB6 inhibitor), pazopanib (TAOK3 inhibitor) with bosutinib (GCK 
inhibitor), foretinib (CDK7 inhibitor) with bosutinib (GCK inhibitor) 
and nintedanib (PCTK1 inhibitor) with enzastaurin (GSK3b inhibitor) 
(Figure 18). 
 
These results suggest that the systems biology approach, which utilizes 
polypharmacology and functional screening data, helps to identify cell-
line specific vulnerabilities or pathway addictions. In contrast to the 
limited power of genomic approaches in predicting druggable targets, 
phenotypic-profiling based approach provided an unprecedented 
opportunity to de-convolve druggable driver alterations. The KISS 
approach can be implemented in future precision therapy based drug 
development since it allows to dissect the unintended target specificities 
from the phenotypic screening data and provide mono and multi-target 







This study highlights the need to go beyond the mere cell viability 
readouts for drug sensitivity assessment of the cell lines or primary 
cancer cells. Since cell viability does not directly correlate to 
proliferation or cell death, a simple multiplexed cell viability and 
cytotoxicity readout can provide more insights into the drug mode-of-
action, hence aiding the design of rational treatment options. With this 
simple approach, we found several investigational oncology compounds 
that failed to induce cell line specific cytotoxicity, but rather only caused 
a reversible cytostatic or anti-metabolic effect against TNBC cell lines. 
As the effect of such cytostatic drugs can be reversed, these drugs should 
perhaps be used cautiously in the clinic.  
 
Currently available high throughput screening-compatible assays for 
measuring cell viability and toxicity still have many limitations. They do 
not provide much information about the mechanisms of drug 
treatment-derived cytopathological changes. With such assays, the 
mechanism of cell toxicity cannot be addressed. For example, they 
cannot distinguish between apoptosis and necrosis or immunogenic cell 
death. The intra-tumor heterogeneity, which is a crucial aspect in 
primary samples, cannot be captured with the current toxicity 
measurements assays. These assays do not differentiate between the 
responder and non-responder cell populations. Such end-point toxicity 
assays do not tell much about physiological drug responses as well, like 
drug kinetics, metabolism, and its mechanism of action. This limits the 
detection of sensitivities to all classes of cancer drugs. To some extent, 
most of these limitations in high throughput chemical screening 
approach can be addressed with high content microscopy. Technological 
advancements in high throughput live imaging and establishment of 
optimal molecular markers are likely to enable deep understanding of 
drug effects. 
 
Real-time measurement systems provide us an opportunity to de-
convolute various types of drug responses including cytostatic, cytotoxic 
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and growth stimulatory effects only from cell viability measurements. A 
simple two-step normalization technique we called NDR, significantly 
reduced the false hit calling and increased the consistency and 
reproducibility in high throughput drug screening approaches. This 
approach will be a significant asset for future cell based high throughput 
drug screenings as it saves time, effort and cost by eliminating the need 
to perform cytotoxicity assays or replicate screens. The NDR approach 
is widely applicable not only for established cell lines but also against 
technically challenging and slow growing patient derived samples. With 
the technological advancements in multi-time point high-content 
imaging adapted for high throughput setting, the application of NDR 
could also be easily expanded to imaging data for more accurate 
evaluation of the effect of drugs on cells. Moreover, the effect of drugs 
could be accurately assessed at subpopulation level (eg. persister cells) 
and in co-culture system.  
 
In this work, we categorized TNBC cell lines into sensitive and 
insensitive groups based on whether mitotic inhibitors induced 
cytotoxic vs. cytostatic responses. Selective cytotoxic responses to 
mitotic inhibitors among the TNBC cell lines could be linked to 
differential expression of protein markers, such as high levels of PKCα, 
FGFR1, c-Jun, Caveolin-1 expression and low levels of RAB25, 
pSTAT3(Y705), NOTCH3, Bcl-2. This highlights the possibility of 
exploring the expression of these molecules for patient stratification and 
therapy against mitotic inhibitors like taxanes. This also suggests that 
protein biomarkers may better predict the therapeutic responses to 
many drugs than genomic biomarkers. 
 
Kinase inhibitors possess great potential in cancer therapeutics as they 
regulate pathways responsible for cell survival and proliferation [108]. 
However, because most of the kinase inhibitors target the highly 
conserved ATP binding site of kinases [189], they are known to be 
promiscuous, making it tough to pinpoint the selective inhibition of an 
individual kinase. Most of the clinically effective kinase inhibitors are 
relatively promiscuous and their polypharmacology effect resulting in 
the concurrent blocking of complementary pathways may be the reason 
behind their clinical significance [131, 134]. To address these challenges, 
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we developed a systems network pharmacology approach, which 
integrated drug sensitivity profiles and kinase target space of the 
respective drugs to identify and establish cell line specific kinase 
addictions or co-addictions. With the KISS approach, we predicted and 
validated selective kinase dependencies and co-dependencies in TNBC 
cell lines, for instance co-dependencies like CDK7 & GSK3B and MEK5 
& AURKC in HCC1937 cell line. Our approach can be easily expanded or 
applied to patient derived samples to identify the molecular addictions 
driving cancer progression and relapse, thereby stratifying tailored drug 
or drug combination approaches for individual patients.  
 
The absence of highly recurrent targetable genomic driver mutations 
and molecular alterations in TNBCs limits the possibilities of 
therapeutic design directly targeting a particular driver oncogene. In 
addition, TNBC is not only a heterogeneous disease with respect to its 
molecular characteristics, but it also exhibits marked heterogeneity in 
its phenotypic responses to drugs. We and others found that the overall 
drug sensitivity correlates poorly with the transcriptomics based 
subtyping of TNBC [22, 90]. Therefore, I belive that drug sensitivity-
based functional profiling of large and diverse panels of TNBC samples 
(cell lines or patient-derived primary samples) along with their putative 
biomarkers can provide better ways to stratify TNBCs for the 
development of effective therapeutics.  
 
The observations in this study were based on drug sensitivity assays of 
conventional TNBC cell lines. Therefore, further studies on alternative 
cancer models that more closely recapitulate the primary tumor 
features, such as patient tumor derived cells (PDC) [190] or xenograft 
(PDX) cell lines [191] or conditionally reprogrammed progenitor-like 
cells (CRC) [192, 193] may provide better ways to stratify and find 
promising therapeutic targets. Although these approaches are in 
preliminary stages of development, they allow the possibility for testing 
ex vivo drug responses in high-throughput settings. Further, emerging 
techniques like patient tumor ex vivo 3D- organoid cultures or 
organotypic tissue slice systems provide a possibility to profile more 
realistic and complex tumor models [194-197]. These models better 
capture the tumor characteristics such as intra-tumor heterogeneity and 
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tumor microenvironment which play a major role in determining drug 
efficacy [197-199]. However, it has been difficult to adapt these 
techniques to high throughput settings. In summary, functional 
profiling allows unbiased determination of new druggable signaling 
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Appendix 1: List of compounds used in the 
studies.  
 





Pilocarpine Non-selective muscarinic receptor agonist Approved 40000 I 
Gefitinib EGFR inhibitor Approved 10000 I, III 
Metformin AMPK activator Approved (non-oncology) 100000 II 
Anagrelide PDE-3, PLA2 inhibitor Approved 10000 I, II 
Imatinib Abl, Kit, PDGFRB inhibitor Approved 10000 I, II, III 
Idarubicin Topoisomerase II inhibitor Approved 1000 I, II 
Vatalanib VEGFR-1 & -2 inhibitor Investigational (Ph 3) 10000 I, III 
Erlotinib EGFR inhibitor Approved 10000 I, II, III 
Dexamethasone Glucocorticoid, immunomodulatory agent Approved 10000 I, II 
Auranofin Antirheumatic agent Approved 2500 I 
Tretinoin Retinoic acid receptor agonist Approved 10000 I, II 
Simvastatin HMG CoA reductase inhibitor Approved (non-oncology) 10000 I 
Goserelin Gonadotropin releasing hormone superagonist Approved 10000 I 
Raloxifene Selective estrogen receptor modulator Approved 10000 I 
Camptothecin Topoisomerase I inhibitor Probe 5000 I 
Plicamycin RNA synthesis inhibitor Approved 10000 I 
Rofecoxib COX-2 inhibitor Approved 10000 I 
Lapatinib HER2, EGFR inhibitor Approved 1000 I, III 
Bortezomib Proteasome inhibitor (26S subunit) Approved 1000 I, II 
Letrozole Aromatase inhibitor Approved 10000 I 
Bexarotene Antineoplastic agent Approved 10000 I 
Celecoxib Selective COX-2 inhibitor Approved 10000 I, II 
Anastrozole Aromatase inhibitor Approved 10000 I 
Bicalutamide Nonsteriodal antiandrogen Approved 10000 I 
Clofarabine Antimetabolite; Purine analog Approved 10000 I, II 
Lomustine Alkylating nitrosourea compound Approved 10000 I 
Vincristine Microtubule depolymerizer Approved 1000 I, II 
Vinorelbine Microtubule depolymerizer Approved 10000 I 
Altretamine Formaldehyde release, alkylating agent Approved 10000 I 
Aminoglutethimide Anti-steroid, aromatase inhibitor Approved 10000 I 
Vinblastine Microtubule depolymerizer Approved 1000 I 
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Chlorambucil Nitrogen mustard alkylating agent Approved 10000 I 
Thalidomide Immunosuppresant Approved 10000 I 
Clomifene Selective 0estrogen receptor modulator Approved 10000 I 
Dacarbazine Alkylating agent Approved 10000 I 
Cyclophosphamide Alkylating agent Approved 40000 I 
Cytarabine Antimetabolite, interferes with DNA synthesis Approved 10000 I, II 
Finasteride type II 5-  reductase inhibitor Approved 10000 I 
Fluorouracil Antimetabolite Approved 10000 I 
Flutamide Nonsteroidal antiandrogen Approved 10000 I 
Ifosfamide Nitrogen mustard alkylating agent Approved 10000 I 
Imiquimod Immunomodulatory agent, TLR7 agonist Approved 2500 I 
Levamisole Immunomodulatory agent Approved 10000 I 
Melphalan Nitrogen mustard alkylating agent Approved 12500 I 
Methylprednisolone Glucocorticoid, immunomodulatory agent Approved 10000 I, II 
Mitoxantrone Topoisomerase II inhibitor Approved 1000 I, II 
Paclitaxel Mitotic inhibitor, taxane microtubule stabilizer Approved 1000 I, II 
Prednisolone Glucocorticoid, immunomodulatory agent Approved 10000 I 
Procarbazine Alkylating agent Approved 10000 I 
Prednisone Immunomodulatory agent Approved 10000 I 
Mepacrine Unclear. PLA2 inhibitor. NF- κB inhibitor, p53 activator Approved 50000 I, II 
Topotecan Topoisomerase I inhibitor. Camptothecin analog Approved 10000 I, II 
Temozolomide Alkylating agent Approved 100000 I 
Fulvestrant Estrogen receptor antagonist Approved 1000 I 
Megestrol acetate Progestogen Approved 10000 I 
Tamoxifen Estrogen receptor antagonist Approved 10000 I 
Mechlorethamine Nitrogen mustard alkylating agent Approved 1e+05 I 
Methotrexate Antimetabolite; Anti-folate agent Approved 5000 I, II 
Nilutamide Nonsteroidal antiandrogen Approved 10000 I 
Mitotane Antineoplastic agent Approved 10000 I 
Allopurinol Xanthine oxidase inhibitor Approved 10000 I 
Busulfan Alkylating antineoplastic agent Approved 1e+05 I 
Deferoxamine Iron chelator Approved (non-oncology) 10000 I 
Hydroxyurea Antineoplastic agent Approved 1000000 I, II 
Mercaptopurine Antimetabolite Approved 10000 I 
Thioguanine Antimetabolite; Purine analog Approved 10000 I 
Carmustine Alkylating agent Approved 10000 I 
Thio-TEPA Alkylating agent Approved 50000 I 
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Pipobroman Alkylating agent Approved 10000 I 
Tacrolimus Binds FKBP12, causes inhibition of calcineurin Approved 10000 I 
AT 101 Bcl-2 family inhibitor Investigational (Ph 2) 100000 I 
BI 2536 PLK1 inhibitor Investigational (Ph 2) 1000 I, III 
Pravastatin HMG CoA reductase inhibitor Approved (non-oncology) 10000 I, II 
Exemestane Aromatase inhibitor Approved 10000 I 
Irinotecan Topoisomerase I inhibitor Approved 10000 I 
Palbociclib CDK4/6 inhibitor Approved 10000 I, II 
AT9283 Aurora A & B, Jak2, Flt, Abl inhibitor Investigational (Ph 2) 1000 I 
Navitoclax Bcl-2/Bcl-xL inhibitor Investigational (Ph 2) 10000 I, II 
Selumetinib MEK1/2 inhibitor Investigational (Ph 3) 10000 I, III 
Veliparib PARP inhibitor Investigational (Ph 3) 10000 I, II 
Afatinib EGFR inhibitor Approved 1000 I, II, III  
Dovitinib FGFR inhibitor Investigational (Ph 3) 10000 I, III 
Obatoclax Bcl-2 family inhibitor Investigational (Ph 3) 10000 I 
Crizotinib ALK, c-Met inhibitor Approved 1000 I, II, III  
Danusertib Aurora, Ret, TrkA, FGFR-1 inhibitor Investigational (Ph 2) 10000 I 
Foretinib MET, VEGFR2 inhibitor Investigational (Ph 2) 1000 I, III 
Abiraterone P450 17 -hydroxylase-17,20-lyase inhibitor Approved 5000 I 
Tanespimycin HSP90 inhibitor Investigational (Ph 2) 10000 I 
Alvespimycin HSP90 inhibitor Investigational (Ph 2) 1000 I 
SNS-032 CDK inhibitor Investigational (Ph 2) 10000 I, III 
ABT-751 Microtubule depolymerizer. Investigational (Ph 2) 10000 I 
Serdemetan HDM2-p53 antagonist Investigational (Ph 1) 10000 I 
BIIB021 HSP90 inhibitor Investigational (Ph 2) 10000 I 
CUDC-101 HDAC & EGFR, Her2 inhibitor Investigational (Ph 1) 10000 I 
Decitabine Nucleoside analog DNA methyl transferase inhibitor Approved 10000 I 
Alvocidib CDK inhibitor Investigational (Ph 2) 10000 I, II, III 
Amonafide Topoisomerase II inhibitor / DNA intercalator Investigational (Ph 3) 10000 I 
Tipifarnib Farnesyltransferase inhibitor Investigational (Ph 3) 10000 I, II 
Pimasertib MEK1/2 inhibitor Investigational (Ph 2) 10000 I 
Ponatinib Broad TK inhibitor Approved 1000 I, II 
Perifosine AKT/PI3K inhibitor Investigational (Ph 3) 2500 I 
Motesanib VEGFR, PDGFR, Ret, Kit inhibitor Investigational (Ph 2) 10000 I, III 
Cediranib KDR/Flt/VEGFR inhibitor Investigational (Ph 3) 1000 I, III 
PF-04691502 PI3K/mTOR inhibitor Investigational (Ph 2) 10000 I 
Rucaparib PARP inhibitor Approved 10000 I 
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Tarenflurbil -secretase inhibitor Investigational (Ph 3) 10000 I 
Tivozanib VEGFR1, 2, 3, c-Kit, PDGFRB inhibitor Investigational (Ph 3) 10000 I 
AZD1775 Wee1 inhibitor Investigational (Ph 2) 10000 I, II 
PF-00477736 Chk1 inhibitor Investigational (Ph 1) 10000 I 
AZD7762 Chk1 inhibitor Investigational (Ph 1) 1000 I 
Barasertib Aurora B inhibitor Investigational (Ph 3) 1000 I, II, III  
AZD8055 mTOR inhibitor Investigational (Ph 1) 10000 I 
Belinostat HDAC inhibitor Approved (US) 10000 I, II 
Bimatoprost Prostaglandin analog Approved 5500 I 
Doramapimod p38MAPK inhibitor Investigational (Ph 1) 10000 I, III 
Bryostatin 1 PKC activator Investigational (Ph 1) 100 I 
Tacedinaline HDAC inhibitor Investigational (Ph 3) 1000 I 
BMS-754807 IGF1R inhibitor Investigational (Ph 2) 10000 I, II 
Idelalisib PI3K inhibitor, p110δ-selective Approved 10000 I, II 
Trametinib MEK1/2 inhibitor Approved 250 I, II 
Sonidegib Smothened (Hh) inhibitor Approved 10000 I 
OSI-027 mTOR inhibitor Investigational (Ph 2) 10000 I 
Refametinib MEK1/2 inhibitor Investigational (Ph 2) 10000 I 
Everolimus binds FKBP12, causes inhibition of mTORC1 Approved 100 I, II 
Ruxolitinib JAK1&2 inhibitor Approved 10000 I, II, III  
Fasudil ROCK, PKA, PKG, PRK inhibitor, prodrug Approved [200] 50000 I 
Indibulin Microtubule depolymerizer Investigational (Ph 2) 10000 I 
Iniparib PARP inhibitor Investigational (Ph 3) 10000 I 
MK-2206 AKT inhibitor Investigational (Ph 2) 1000 I 
Alisertib Aurora A inhibitor Investigational (Ph 3) 10000 I, II 
Nelarabine Nucleoside analog, DNA, RNA synth inhibitor Approved 10000 I 
Nilotinib Abl inhibitor Approved 10000 I, II, III  
Luminespib HSP90 inhibitor Investigational (Ph 2) 1000 I, II 
2-methoxyestradiol Angiogenesis inhibitor Investigational (Ph 2) 10000 I 
Plerixafor CXCR4 antagonist Approved 10000 I 
Vemurafenib B-Raf(V600E) inhibitor Approved 10000 I, II, III 
Vandetanib VEGFR, EGFR, RET inhibitor Approved 1000 I, III 
Sepantronium 
bromide Survivin inhibitor Investigational (Ph 2) 10000 I 
Linsitinib IGF1R, IR inhibitor Investigational (Ph 2) 10000 I 
Tepotinib c-Met inhibitor Investigational (Ph 1) 1000 I 
Lestaurtinib FLT3, JAK2, TrkA, TrkB, TrkC inhibitor Investigational (Ph 3) 1000 I 
Dasatinib Abl, Src, Kit, EphR... Inhibitor Approved 1000 I, II, III  
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Tofacitinib JAK3, JAK2(V617F) inhibitor Approved 5000 I, III 
Fingolimod S1PR antagonist Approved 10000 I 
Axitinib VEGFR, PDGFR, KIT inhibitor Approved 10000 I, II, III 
Saracatinib Src, Abl inhibitor Investigational (Ph 3) 10000 I 
Bosutinib Abl, Src inhibitor Approved 10000 I, II 
Canertinib pan-HER inhibitor Investigational (Ph 3) 10000 I, III 
Lenalidomide Immunomodulatory Approved 100000 I, II 
Panobinostat HDAC inhibitor Approved 1000 I, II 
Pazopanib VEGFR inhibitor Approved 10000 I, III 
Tandutinib FLT3, PDGFR, KIT inhibitor Investigational (Ph 2) 1000 I, III 
Temsirolimus binds FKBP12, causes inhibition of mTORC1 Approved 100 I 
Vorinostat HDAC inhibitor Approved 10000 I, II 
Entinostat HDAC inhibitor Investigational (Ph 2) 10000 I 
Enzastaurin PKC  inhibitor Investigational (Ph 3) 10000 I, III 
Olaparib PARP inhibitor Approved 10000 I, II 
Masitinib KIT inhibitor Investigational (Ph 3) 10000 I, III 
Pictilisib PI3K inhibitor, pan-class I Investigational (Ph 2) 10000 I, III 
Vismodegib Smothened (Hh) inhibitor Approved 10000 I, II 
Sorafenib B-Raf, FGFR-1, VEGFR-2 & -3, PDGFR- , KIT, and FLT3 inhibitor Approved 1000 I, II, III 
Seliciclib CDK2/7/9 inhibitor Investigational (Ph 2) 10000 I 
Patupilone Epothilone microtubule stabilizer Investigational (Ph 3) 1000 I 
Docetaxel Taxane microtubule stabilizer Approved 1000 I 
Pentostatin Antimetabolite; Purine analog Approved 10000 I 
Sirolimus binds FKBP12, causes inhibition of mTORC1 Approved 100 I 
Estramustine Alkylating agent Approved 10000 I 
Floxuridine Antimetabolite; Analog of 5-fluorouracil Approved 10000 I 
Gemcitabine Antimetabolite; Nucleoside analog Approved 1000 I, II 
Teniposide Topoisomerase II inhibitor Approved 10000 I 
Dactinomycin RNA and DNA synthesis inhibitor Approved 1000 I 
Streptozocin Alkylating glucosamine-nitrosourea agent Approved 10000 I 
Cladribine Antimetabolite; Purine analog Approved 1000 I 
Mitomycin C Antineoplastic antibiotic; DNA crosslinker Approved 10000 I 
Carboplatin Platinum-based antineoplastic agent Approved 100000 I 
Cisplatin Platinum-based antineoplastic agent Approved 100000 I 
Pemetrexed Dihydrofolate reductase inhibitor Approved 10000 I 
Oxaliplatin Platinum-based antineoplastic agent Approved 100000 I 
Uramustine Alkylating agent Approved 10000 I 
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Daunorubicin Topoisomerase II inhibitor Approved 1000 I 
Etoposide Topoisomerase II inhibitor Approved 10000 I, II 
Arsenic(III) oxide Thioredoxin reductase inhibitor Approved 2500 I 
Doxorubicin Topoisomerase II inhibitor Approved 1000 I 
Valrubicin Topoisomerase II inhibitor Approved 5000 I 
Sunitinib Broad TK inhibitor Approved 1000 I, II, III 
Ixabepilone Epothilone microtubule stabilizer. Approved 1000 I 
Azacitidine Nucleoside analogue DNA methyl transferase inhibitor Approved 10000 I, II 
Fludarabine Antimetabolite; Purine analog Approved 10000 I, II 
Bleomycin Glycopeptide antibiotic; causes DNA breaks Approved 10000 I 
Dactolisib mTOR/(PI3K) inhibitor Investigational (Ph 2) 1000 I 
Quizartinib FLT3 inhibitor Investigational (Ph 3) 1000 I, II, III  
APR-246 p53 activator, thioredoxin reductase 1 inhibitor Investigational (Ph 1) 10000 I 
Carfilzomib Proteasome inhibitor (20S subunit) Approved 1000 I, II 
Gandotinib JAK2 inhibitor Investigational (Ph 2) 10000 I 
AZ 3146 Mps1 kinase (TTK) inhibitor Probe 10000 I 
S-trityl-L-cysteine Eg5 inhibitor Probe 40000 I 
Sotrastaurin PKC inhibitor Investigational (Ph 2) 10000 I 
Geldanamycin HSP90 inhibitor Probe 10000 I 
Bendamustine Nitrogen mustard alkylating agent Approved 10000 I 
Cyclopamine Smothened inhibitor Probe 10000 I 
Midostaurin Broad TK (FLT3, KIT, RET, JAK, EGFR...) inhibitor Approved (US) 10000 I, II, III  
Regorafenib B-Raf, c-Kit, VEGFR2 inhibitor Approved 10000 I, II 
XAV-939 Tankyrase-1 and -2 Probe 10000 I 
UCN-01 PKC , PDK1, Chk, Cdk2 inhibitor Investigational (Ph 2) 10000 I 
Ruboxistaurin PKC  inhibitor Investigational (Ph 3) 10000 I, III 
Capecitabine 5-FU prodrug Approved 10000 I 
Chloroquine Antimalaria agent; chemo/radio sensitizer Approved 100000 I, II 
Valproic acid HDAC inhibitor Approved 1000000 I, II 
Tivantinib MET inhibitor Investigational (Ph 2) 1000 I 
Niraparib PARP inhibitor Approved (US) 10000 I 
Volasertib PLK1 inhibitor Investigational (Ph 3) 1000 I, II 
Toremifene selective estrogen receptor modulator Approved 10000 I 
Lasofoxifene Selective estrogen receptor modulator Approved 1000 I 
Galiellalactone STAT3-DNA interaction inhibitor Probe 25000 I 
Omacetaxine Protein synthesis inhib (80 S ribosome) Approved 10000 I, II 
NVP-RAF265 "C-Raf" inhibitor, unclear MoA Investigational (Ph 2) 1000 I, III 
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Nutlin-3 MDM2 inhibitor Probe 10000 I 
Neratinib EGFR inhibitor Approved (US) 1000 I 
Mocetinostat HDAC inhibitor (HDAC1 & 2-selective) Investigational (Ph 2) 10000 I 
Rabusertib Chk1 inhibitor Investigational (Ph 2) 1000 I 
Galunisertib TGF-B/Smad inhibitor Investigational (Ph 2) 1000 I, II 
Linifanib VEGFR, PDGFR, CSF-1R, FLT3 inhibitor Investigational (Ph 3) 1000 I, III 
Brivanib VEGFR inhibitor Investigational (Ph 3) 1000 I, III 
Buparlisib PI3K inhibitor, pan-class I Investigational (Ph 2) 10000 I 
Nintedanib VEGFR, PDGFR, FGFR inhibitor Approved 10000 I, II, III 
Apitolisib PI3K/mTOR inhibitor Investigational (Ph 2) 10000 I 
AZD4547 FGFR inhibitor Investigational (Ph 2) 1000 I, II 
VER 155008 HSP70 inhibitor Probe 10000 I 
Daporinad NAMPT inhibitor Investigational (Ph 2) 1000 I 
Cabozantinib VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor Approved 1000 I 
AZD1480 JAK1/2, FGFR inhibitor Investigational (Ph 1) 1000 I 
Ridaforolimus binds FKBP12, causes inhibition of mTORC1 Investigational (Ph 3) 100 I 
Sonolisib PI3K inhibitor, pan-class I. Irreversible Investigational (Ph 2) 10000 I 
Quisinostat HDAC inhibitor Investigational (Ph 2) 1000 I 
Tosedostat Aminopeptidase inhibitor Investigational (Ph 3) 10000 I, II 
PF-04708671 p70S6K inhibitor Probe 10000 I 
Binimetinib MEK1/2 inhibitor Investigational (Ph 2) 1000 I 
Tamatinib Syk inhibitor Investigational (Ph 1) 10000 I 
KX2-391 non-ATP competitive Src inhibitor Investigational (Ph 2) 10000 I 
PF-3845 FAAH inhibitor Probe 10000 I 
MK-0752 -secretase/notch inhibitor Investigational (Ph 2) 1000 I, II 
TAK-733 MEK1/2 inhibitor Investigational (Ph 1) 1000 I 
SB 743921 Mitotic inhibitor. Eg5/KSP inhibitor Investigational (Ph 2) 100 I 
Omipalisib PI3K/mTOR inhibitor Investigational (Ph 1) 1000 I 
Ibrutinib Btk inhibitor Approved 1000 I, II 
TAK-901 Aurora, Src family, JAK3, RTK inhibitor Investigational (Ph 1) 1000 I 
Fostamatinib Syk inhibitor Investigational (Ph 2) 2500 I, III 
JQ1 BET family inhibitor Probe 10000 I 
(-) JQ1 Inactive stereoisomer of (+) JQ1 Probe 10000 I 
Infigratinib FGFR inhibitor Investigational (Ph 1) 1000 I, II 
Momelotinib JAK1 & 2 inhibitor Investigational (Ph 2) 10000 I, II 
Sapanisertib mTOR inhibitor Investigational (Ph 1) 1000 I, II 
PIK-75 PI3Kα selective inhibitor Probe 10000 I 
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TGX-221 PI3K  selective inhibitor Probe 10000 I 
Tubacin HDAC6 inhibitor Probe 10000 I 
Tubastatin A HDAC6 inhibitor Probe 10000 I 
Atorvastatin HMG CoA reductase inhibitor Approved 10000 I 
Varespladib Secretory phospholipase A2 inhibitor Investigational (Ph 2) 10000 I 
StemRegenin 1 AHR antagonist, stem cell regenerating Probe 10000 I 
VX-11E ERK1 & 2 inhibitor Probe 2500 I 
PFI-1 BET family inhibitor Probe 30000 I 
4-hydroxytamoxifen Selective estrogen receptor modulator Investigational (Ph 2) 10000 I 
15D-PGJ2 
Endogenous PPARγ ligand, 
prostaglandin, NFκB signaling 
inhibitor 
Probe 3000 I 
RD162 AR antagonist Probe 10000 I 
Enzalutamide AR antagonist Approved 10000 I 
1-methyl-D-
tryptophan 
Indolamine 2,3-dioxygenase 1 and 
2 inhibitor Investigational (Ph 2) 5000 I 
Dacomitinib pan-HER inhibitor Investigational (Ph 3) 1000 I 
Dinaciclib CDK inhibitor Investigational (Ph 3) 1000 I, II 
Dabrafenib B-Raf(V600E) inhibitor Approved 2500 I 
I-BET151 BET family inhibitor Probe 10000 I 
Ralimetinib p38MAPK inhibitor Investigational (Ph 2) 10000 I, II 
Crenolanib PDGFRA and PDGFRB inhibitor Investigational (Ph 2) 10000 I, II 
PF-4800567 CK1epsilon inhibitor Probe 10000 I 
PF-670462 CK1epsilon and CK1  inhibitor Probe 10000 I 
ZSTK474 PI3K  selective inhibitor Investigational (Ph 1) 10000 I, II 
PAC-1 procaspase-3 activator Investigational (Ph 1) 10000 I 





Investigational (Ph 2) 10000 I, II 
Roxadustat HIF prolyl hydroxylase inhibitor Investigational (Ph 2) 10000 I, II 
Pevonedistat NAE inhibitor Investigational (Ph 1) 10000 I, II 
GSK2636771 PI3K  selective inhibitor Investigational (Ph 1) 10000 I 
AT-406 XIAP, cIAP1, cIAP2 inhibitor Investigational (Ph 1) 10000 I 
(5Z)-7-Oxozeaenol TAK1 inhibitor Probe 10000 I 
Rebastinib Allosteric ABL, FLT3, TIE2, TRKA inhibitor Investigational (Ph 1) 1000 I 
Lomeguatrib O6-methylguanine-DNA methyltransferase inhibitor Investigational (Ph 2) 10000 I 
GSK269962 ROCK1 and ROCK2 inhibitor Probe 10000 I 
PF 431396 FAK/PYK2 inhibitor Probe 10000 I 
GSK650394 SGK1 & 2 inhibitor Probe 10000 I 
AVN944 IMPDH inhibitor Investigational (Ph 2) 10000 I 
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Venetoclax Bcl-2-selective inhibitor Approved 1000 I, II 
BMS-911543 JAK2 inhibitor Investigational (Ph 1) 10000 I 
Ipatasertib AKT inhibitor Investigational (Ph 2) 10000 I, II 
IOX-2 PHD2 inhibitor Probe 50000 I 
GSK-J4 JMJD3 (histone demethylase) inhibitor Probe 100000 I 
UNC1215 L3MBTL3 inhibitor Probe 10000 I 
SGC0946 DOT1L inhibitor Probe 10000 I 
UNC0642 G9a/GLP inhibitor Probe 10000 I 
GSK343 EZH2 inhibitor Probe 1000 I 
UNC0638 G9a/GLP inhibitor Probe 10000 I 
C646 p300/CREB-binding protein (CBP) inhibitor Probe 25000 I 
Stattic STAT3 SH2 domain inhibitor Probe 50000 I 
Rocilinostat HDAC-6 selective inhibitor Investigational (Ph 1) 10000 II 
Lonafarnib Farnesyl transferase inhibitor Investigational (Ph 3) 100000 II 
Alpelisib PI3K  inhibitor Investigational (Ph 2) 2500 II 
Pomalidomide Immunomodulatory agent, anti-angiogenic Approved 10000 II 
SGI-1776 PIM kinase inhibitor Investigational (Ph 1) 10000 II 
Rigosertib Ras-Raf interaction inhibitor Investigational (Ph 3) 10000 II 
Duvelisib PI3K inhibitor Investigational (Ph 3) 500 II 
SCH772984 ERK1 & 2 inhibitor Probe 10000 II 
Abemaciclib CDK4/6 inhibitor Investigational (Ph 3) 2500 II 
Ceritinib ALK inhibitor Approved 2500 II 
Hydroxyfasudil ROCK, PKA, PKG, PRK inhibitor (Approved Japan) 19000 II 
Gedatolisib PI3K/mTOR inhibitor Investigational (Ph 2)) 1000 II 
AZD-1080 GSK3 inhibitor Investigational (Ph 1) 10000 II 
Silmitasertib CSNK2A1 inhibitor Investigational (Ph 2) 10000 II 
AZD-8186 PI3K  inhibitor Investigational (Ph 1) 1000 II 
NVP-LCL161 IAPs, SMAC mimetic Investigational (Ph 2) 25000 II 
Tazemetostat EZH2 inhibitor Investigational (Ph 2) 10000 II 
Pinometostat DOT1L inhibitor Investigational (Ph 1) 1000 II 
Selinexor CRM1 inhibitor Investigational (Ph 2) 10000 II 
Birabresib BET family inhibitor Investigational (Ph 2) 10000 II 
NVP-LGK974 PORCN inhibitor Investigational (Ph 1) 10000 II 
Pacritinib FLT3/JAK2 Investigational (Ph 3) 10000 II 
Idasanutlin MDM2 inhibitor Investigational (Ph 3) 10000 II 
Filanesib KSP/Eg5 inhibitor Investigational (Ph 2) 1000 II 
Cobimetinib MEK1/2 inhibitor Approved (US) 1000 II 
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AZD1208 PIM1, 2, 3 kinase inhibitor Investigational (Ph 1) 10000 II 
BGB324 Axl inhibitor Investigational (Ph 1) 10000 II 
Entospletinib SYK inhibitor Investigational (Ph 2) 5000 II 
AMG-232 MDM2 inhibitor Investigational (Ph 2) 10000 II 
GSK525762 BET family inhibitor Investigational (Ph 1) 10000 II 
Taselisib PI3K , , ( ) selective inhibitor Investigational (Ph 3) 1000 II 
Glasdegib Smo inhibitor Investigational (Ph 2) 1000 II 
A-1210477 MCL-1 inhibitor probe 50000 II 
VS-4718 FAK inhibitor Investigational (Ph 1) 10000 II 
Ulixertinib ERK inhibitor Investigational (Ph 2) 10000 II 
LY3009120 pan-RAF inhibitor Investigational (Ph 1) 10000 II 
Prexasertib Chk1 inhibitor Investigational (Ph 2) 10000 II 
Epacadostat IDO inhibitor Investigational (Ph 3) 10000 II 
Napabucasin CSC inhibitor, STAT3 mediated Investigational (Ph 3) 20000 II 
Enasidenib IDH2-R140Q inhibitor Approved (US) 10000 II 
CCT196969 pan-RAF/Src inhibitor Probe 25000 II 
Gilteritinib FLT3/AXL inhibitor Investigational (Ph 3) 1000 II 
A-1331852 Bcl-XL inhibitor Probe 1000 II 
Ivosidenib IDH1 R132H/R132C inhibitor Investigational (Ph 2) 10000 II 
TIC10 ERK & AKT inhibitor, TRAIL inducer Investigational (Ph 2) 25000 II 
ABC294640 Sphingosine kinase 2 inhibitor Investigational (Ph 2) 50000 II 
RO5126766 dual RAF/MEK inhibitor Investigational (Ph 1) 1000 II 
AZD6738 ATR inhibitor Investigational (Ph 1) 25000 II 
Entrectinib TRK, ROS1, ALK inhibitor Investigational (Ph 2) 1000 II 
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